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ABSTRACT
Discovery and characterization of biomarkers for Alzheimer’s Disease pathology
Josue David Gonzalez Murcia
Department of Biology, BYU
Doctor of Philosophy
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is the
main cause of dementia in the elderly population. AD is pathologically characterized by the
accumulation of amyloid plaques and neurofibrillary tangles that results in neurodegeneration
and loss of memory function. However, diagnosis of AD and characterization of biological
mechanisms that lead to pathology and modulate risk for disease has proven to be extremely
difficult.
Cerebrospinal fluid (CSF) contains critical biomarkers for AD such as levels of amyloid
beta (Aβ) phosphorylated-tau (p-tau), total-tau (t-tau), and neurofilament light chain (NfL). The
CSF levels of these biomarkers are useful in determining AD status in a patient, but data
collection can be time consuming, technically difficult, and expensive. While still subject to the
limitations of obtaining CSF, cell free single stranded DNA (cfssDNA) is much cheaper and
more reliably measured than these biomarkers. We investigated cfssDNA as a biomarker for AD
status. We observed an association between low levels of concentration isolated from CSF as a
potential biomarker for diagnosis of AD.
Inflammation is a vital process in the immune system. Acute inflammation plays an
essential role in the normal response to tissue injury. This inflammatory response initiates a
cascade of cellular activation signals in innate immune cells resulting in increased production of
proinflammatory cytokines and chemokines. These chemokines are essential to the recruitment
and activation of other cells in the innate and adaptive immune system. Deviations from the
normal production of these chemokines can result in disease status.
Recently published work has identified genetic variants that show strong associations
with AD-related chemokine levels in CSF and plasma. We attempted to characterize the
biological mechanisms that underlie the reported associations between the ACKR2-V41A variant
and CCL2 levels and the CCRL2-V180M variant and CCL4 levels. Our data demonstrate that
the ACKR2-V41A receptor has a lower CCL2 binding affinity, scavenging efficiency, and
receptor upregulation compared to ACKR2-WT. For CCRL2-V180M our data demonstrate
higher binding affinity with chemerin and CCL19 than CCRL2-WT. Our data also show that
while CCRL2-V180M and CCRL2-WT do not directly bind with CCL4, interactions between
CCRL2-V180M and CCL19 alter the secretion of CCL4 from leukocytes.
These findings provide evidence for a novel biomarker for AD diagnosis, mechanistic
insights into the functional impact of common genetic variants on chemokine levels, and
highlight a potential role of atypical chemokines in altering the risk for AD.
Keywords: Alzheimer’s disease, inflammation, chemokines, diagnosis.
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CHAPTER 1: Introduction to Neuroinflammation and its role in Alzheimer’s disease
The first known case of Alzheimer’s disease (AD) was reported in 1906 when Dr. Alois
Alzheimer noticed structural changes in the brain of a women who had died of unusual mental
illness. AD is currently a fatal neurodegenerative condition ranked as the sixth leading cause of
death in the United States of America 1. AD is an emotional and financially devastating disease
for those affected as well as for their caregivers. The total cost of caring for those with AD was
reported in 2015 to be $600 billion per year and the amount could rise as high as $1.1 trillion by
2050 2. Despite the elevated cost for caregiver and government expenses, there is not an adequate
method to prevent, treat, and cure the disease 3,4. The neuropathology of AD is characterized by
synaptic and neuronal loss, gliosis, and peptide aggregation in the gray matter. 5-7. AD is a
complex neurodegenerative disease that requires the involvement of experts across
multidisciplinary fields to provide an accurate diagnosis. Current clinical diagnosis of AD takes
family history, symptoms, laboratory and neuroimaging testing, cognitive impairment level,
cognitive behavior, and biomarker levels under consideration 8.
AD clinical symptoms are accompanied by the accumulation of the insoluble peptide
amyloid-beta (Aβ) in fibrillary plaques in the extracellular space of the brain 9. In addition,
neurofibrillary tangles composed of hyperphosphorylated tau protein form in the cytoplasm of
neurons 10. Aβ and tau protein levels in CSF have been extensively studied. They are used as
proxies for these pathological features and are often used as fluid biomarkers of AD 11-13.
However, the CSF levels of Aβ, p-tau and t-tau greatly differ between patients by age, stage of
disease, and genotype 7. This variability hinders a standardization of required thresholds of Aβ
and tau levels in CSF to determine AD status. Significance efforts to solve issues with
measurement variability and create consistency between labs are ongoing 7,14. Neurofilament
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light chain (NfL) in CSF is another potential biomarker for AD 15,16. NfL is a major component
of the neuronal cytoskeleton, and soluble NfL can be detected in CSF and plasma 17. NfL lacks
specificity as a biomarker for AD due to substantial overlap between AD, amnestic mild
cognitive impairment (aMCI), and mild cognitive impairment (MCI) cases 18. Several other CSF
and plasma analytes have been implicated by recent work and may prove to be useful biomarkers
pending further evaluation 19-24.
Inflammation is a process associated with increased risk of developing AD 34. Acute
inflammation plays an essential role in the normal response to tissue injury 35,36. This
inflammatory response initiates a cascade of cellular activation signals in innate immune cells
(e.g. macrophages, mast cells, and endothelial cells), resulting in increased production of
proinflammatory cytokines and chemokines 37-39. These cytokines and chemokines are essential
to the recruitment and activation of other cells in the innate and adaptive immune system. An
abnormal response to inflammation or alterations in the production of these chemokines can
result in disease development.
Significant progress has been made towards understanding the genetic architecture of
AD. To date, 32 loci have been identified with over 600 common and rare alleles that influence
the risk of AD 2,40,41; of which 11 loci have a direct role in the immune response or inflammation
regulation 42 (Table 1.1). However, the characterization of biological mechanisms by which these
rare variants and the deposition of biomarkers associated with AD, such as Aβ, tau, and NfLs,
modulate risk for disease has proven to be extremely difficult, with only several of these variants
being experimentally characterized in a relevant cell lineages such as microglia2,23,43-49.
Microglia act as macrophages in the central nervous system (CNS) and are mainly
distributed in the brain 37. Microglia are highly mobile and their main function is to search for the
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presence of pathogen and cellular debris 50. Microglia provide tissue maintenance and
communication between immune cells and neurons through a number of signaling pathways and
preserve synapsis and plasticity of neuronal circuit 51-53. Microglia are activated through binding
of DAMPs/PAMPS receptors with protein debris, aggregates, and neuronal death 54. In AD,
microglia bind to soluble Ab oligomers and Ab fibrils via class A scavenger receptors A1,
CD36, CD14, a6b1 integrin, CD47, and toll like receptors (TLR2, TLR4, TLR6, and TLR9) 5558

. The binding of Ab with CD26, TLR4, and TLR6 incentivizes microglia activation and

production of proinflammatory chemokines to regulate immune response and activity 59.
Recent analyses of quantitative AD endophenotypes in cerebrospinal fluid (CSF) have
identified two atypical chemokine receptor variants altering the levels of chemokine ligands
associated with increasing the risk to develop AD 60. This genome-wide association study
(GWAS) of 59 AD-related CSF analytes used data from the Knight Alzheimer’s Disease
Research Center at Washington University in St. Louis and Alzheimer’s Disease Neuroimaging
Initiative 60. This study demonstrated an association between increased levels of chemokine
ligand 2 (CCL2) with atypical chemokine receptor chemokine-binding protein 2 (ACKR2)
variant V41A. Another significant association in the study revealed decreased levels of
chemokine ligand 4 (CCL4) with atypical C-C motif chemokine receptor – like 2 (CCRL2)
variant V180M.
CCL2 is also known as monocyte chemotactic protein-1 (MCP-1) and is encoded by the
CCL2 gene located on chromosome 17q11.2-q12. CCL2 is a pro-inflammatory chemokine
involved in recruitment of immune cells from the blood to sites of inflammation via chemokine
gradients. CCL2 helps to control blood brain barrier migration of monocytes and dendritic cells
and aids in the differentiation and migration of macrophages 61. In the brain, CCL2 is mainly

3

secreted by astrocytes, microglia, and in low levels, by endothelial cells 62. Upon an immune
response to infection, injury, or inflammation, CCL2 is produced in the central nervous
system (CNS) 63. CCL2 interacts with chemokine receptor CCR2 which signals via a Gcoupled protein cascade. Upon CCR2 and CCL2 ligand interaction, a cascade of cell
activation events takes place [i.e. activation of protein kinase C (PKC), calmodulin-dependent
protein kinase II (CaMKII), PI3K, Akt, and ERK]. This activation cascade signals cell
migration, cell survival, transcription regulation, and release of pro-nociceptive molecules
64,65

. Upon CCL2 binding to a receptor, it induces a strong chemotactic response and

mobilization of intracellular calcium ions and synaptic network activity in the hippocampal
neurons 66,67. High levels of CCL2 is a risk factor in several neuroinflammatory and
neurodegenerative brain diseases such as multiple sclerosis, brain ischemia, traumatic brain
damage, and AD 68. In AD mouse models, CCL2 is key to inducing chronic inflammation and
activation of immune cells, and secretion of other chemokines 69. Overexpression of CCL2
retains activated microglia cells near the inflamed site 70. This results in increased interactions of
activated microglia with key features of AD: amyloid plaques, plague aggregation, and cognitive
decline 71-73. Inhibition or removal of CCL2 in AD mouse models revealed accelerated amyloid
pathology formation 74. These studies demonstrate that proper function and regulation of CCL2
is imperative to preserve brain innate immune response homeostasis and cognitive function.
Atypical chemokine receptor 2 (ACKR2 75) is encoded by the ACKR2 gene located on
chromosome 3p21.3. ACKR2 is a seven transmembrane G-protein-coupled receptor containing
three intracellular loops and three extracellular loops 76. ACKR2 binds with the 14 inflammatory
chemokines of the CC family, including CCL2 and CCL4, but not CCL19 77. ACKR2 is an
atypical chemokine due to its lack of a canonical DRYLAIV motif in the second extracellular
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loop. This lack of motif inhibits the ability of the receptor to signal the production of other
cytokines 76. Instead, ACKR2 recognizes inflammatory chemokines, scavenges them, and
upregulates the production of more ACKR2 receptor 78. ACKR2 plays an essential role in the
regulation of the inflammatory response by internalizing inflammatory chemokines, facilitating
their destruction when the cellular endosome fuses with an acidic lysosome. The chemokine-free
ACKR2 receptor is then recycled back to the cell surface and can scavenge additional
inflammatory chemokines 79. ACKR2 is mainly expressed on leukocytes, including dendritic
cells, monocytes, macrophages, and innate-like B cells 80. In the central nervous system (CNS),
ACKR2 is mainly expressed in microglia and astrocyte cells 81-83. Nonsynonymous mutations
mapped to the ACKR2 gene producing a loss of function of the protein have been associated with
increased risk for breast cancer, testicular leukemia, CD45 deficiency, glucose intolerance and
inhibit leukocyte type differentiations and monocyte counts 84-89 .
The ACKR2-V41A allele is associated with altered chemokine levels in the CSF and
plasma A 2017 study with 8,293 Finn participants reported an association between the
V41Avariant and increased levels of the chemokine eotaxin (a potent eosinophil attractant) as
well as increased risk of developing Crohn’s disease, multiple sclerosis, and ulcerative colitis 90.
In another study involving over 11,000 subjects from the electronic Medical Records and
Genomics Network (eMERGE), this variant was associated with increased coronary heart
disease and a higher monocyte count in the blood stream 84,91. ACKR2-V41A variant was also
identified as an increased risk factor for developmental disorders following the analysis of over
700 mother-infant pair mid-gestational serum and neonatal bloodspots 92. Another group used the
National Human Genome Research Institution (NHGRI) dataset and reported association
between the V41A variant and increased AD risk 93. Together these studies make a compelling
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case that the biological characterization of ACKR2-V41A will provide insights into the
pathology of AD and a variety of diseases and phenotypes related to inflammatory dysfunction.
GWAS analysis have proposed that lower levels of CCL4 in CSF are associated with
CCRL2-V180M 60. CCL4, also known as macrophage inflammatory protein-1β (MIP-1-b),
activates cellular migration of eosinophils, neutrophils, lymphocytes, and monocytes 94-96. CCL4
induces the synthesis and release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF
from fibroblasts and macrophages contributing to an inflammatory cytokine response 97,98. CCL4
ligand is known to bind to C-C chemokine receptor type 5 (CCR5) 99,100 and C-C chemokine
receptor 1 (CCR1) facilitating trafficking of leukocytes to the inflammation site 101. In AD cell
and mouse models, CCL4 is predominantly expressed in activated subpopulations of astrocytes
and microglia 102,103. Several independent studies evaluating AD have demonstrated that CCL4
levels are elevated in AD animals and cell cultures models in response to brain inflammation 104106

. Together these studies suggest that high levels of chemokine CCL4 are correlated with Ab

peptide aggregation playing a role in the inflammatory response and with altering the rate of
development of AD.
CCRL2, also known as ACKR5, is an atypical chemokine receptor due to its lack of a
canonical DRYLAIV motif in the second extracellular loop, inhibiting the ability to signal 107.
CCRL2 is a seven transmembrane G protein-coupled receptor containing three intracellular and
three extracellular domains 76. CCRL2 is expressed in almost all human hematopoietic cells
including monocytes, macrophages, PMNs, T cells (CD4+ and CD8+), monocyte-derived iDCs,
NK cells, and CD34+ progenitor cells 108-110. CCRL2 has two isoforms known as CRAM-A and
CRAM-B; the CRAM-B isoform is 12 amino acids shorter 111. Both isoforms of CCRL2 are
reported to bind and concentrate chemerin facilitating activation and presentation to CMKLR1
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on adjacent cells 112,113. It has been reported that CRAM-B interacts with CCL5 and CCL19
111,114,115

, however, it is unclear if CRAM-A has similar binding properties with CCL19. Genetic

variants and downregulation of CCRL2 have been associated with elevating the risk to develop
cancer, autoimmunity, and metabolic diseases 82,88,116-120. These studies showing alterations in
binding affinity for chemerin and CCL19 make a strong case for the biological characterization
of CCRL2-V180M variant and its association with lower levels of chemokine ligand CCL4 in
CSF. These discoveries could lead to novel therapeutic solutions for AD and other immune
diseases associated with CCRL2.
Inflammation is a process associated with altering the rate of development of AD.
Inflammation is required to initiate cellular activation signals in innate immune cells and to
respond to tissue injury. Upon activation of the innate immune cells, such as microglia, this
results in the clearance by endocytosis of Aβ aggregates, pathogens, and cellular debris. The
microglia cellular debris could provide cfDNA material which could lead its usage as a potential
biomarker, aiding the diagnosis of AD statues. Another response of activated microglia is the
increased production of proinflammatory cytokines and chemokines, essential for the activation
of additional innate and adaptive immune cells. Here we have exposed two atypical chemokines
variants ACKR2-V41A and CCRL2-V180M altering the levels of chemokine ligand CCL2 and
CCL4 respectively. High levels of CCL2 and CCL4 have been associated with increased risk to
develop AD. The characterization of reported genetic association with chemokine function may
provide important insights into AD pathology, and help find novel biomarkers to improve
diagnosis and therapeutics solutions.
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Table 1.1 Gene associated with altering risk to develop Alzheimer’s Disease with a direct role with
the Immune system.

Locus
CR1
INPP5D

Variant
rs6656401
rs35349669

MEF2C
HLADRB1/5
EPHA1

rs190982

CLU
MS4A(gene
cluster)
TREM2
TREML2
TRIP4
CD33

rs9331896

Immune response and inflammation
Immune and complement systems/inflammatory response
Immune and complement systems/inflammatory
response; cholesterol/lipid metabolism

rs983392
rs75932628/R47H
rs9381040
rs74615166
rs3865444

Immune and complement systems/inflammatory response
Immune response; chronic inflammation
Inflammation regulation
Immune response; endocrine processes
Immune and complement systems/inflammatory response

rs9271192
rs11771145

Potential Biological Process or Pathways Affected
Immune and complement systems/inflammatory response
Immune response and inflammation; APP metabolism
Immune response and inflammation; Hippocampal
synaptic function

8

1.1 References

1.

Maresova, P., et al., Socio-economic Aspects of Alzheimer's Disease. Curr Alzheimer
Res, 2015. 12(9): p. 903-11.

2.

Harold, D., et al., Genome-wide association study identifies variants at CLU and
PICALM associated with Alzheimer's disease. Nat Genet, 2009. 41(10): p. 1088-93.

3.

Lambert, J.-C., et al., Genome-wide association study identifies variants at CLU and CR1
associated with Alzheimer's disease. Nature Genetics, 2009. 41(10): p. 1094-1099.

4.

Hollingworth, P., et al., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33
and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011. 43(5): p.
429-435.

5.

Braak, H., et al., Staging of Alzheimer disease-associated neurofibrillary pathology using
paraffin sections and immunocytochemistry. Acta Neuropathol, 2006. 112(4): p. 389-404.

6.

Hyman, B.T., et al., National Institute on Aging-Alzheimer's Association guidelines for
the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement, 2012. 8(1):
p. 1-13.

7.

Hane, F.T., et al., Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis
and Treatment. J Alzheimers Dis, 2017. 57(3): p. 645-665.

8.

Atri, A., The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med
Clin North Am, 2019. 103(2): p. 263-293.

9.

Schirinzi, T., et al., Levels of amyloid-beta-42 and CSF pressure are directly related in
patients with Alzheimer's disease. J Neural Transm (Vienna), 2017. 124(12): p. 16211625.

10.

Hoglund, K., et al., Alzheimer's disease--Recent biomarker developments in relation to
updated diagnostic criteria. Clin Chim Acta, 2015. 449: p. 3-8.

11.

Dubois, B., et al., Research criteria for the diagnosis of Alzheimer's disease: revising the
NINCDS-ADRDA criteria. Lancet Neurol, 2007. 6(8): p. 734-46.

12.

Andreasen, N., et al., Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for
Alzheimer disease in clinical practice. Arch Neurol, 2001. 58(3): p. 373-9.

13.

Buchhave, P., et al., Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are
fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen
Psychiatry, 2012. 69(1): p. 98-106.

14.

Mattsson, N., et al., The Alzheimer's Association external quality control program for
cerebrospinal fluid biomarkers. Alzheimers Dement, 2011. 7(4): p. 386-395.e6.

15.

Petzold, A., Neurofilament phosphoforms: surrogate markers for axonal injury,
degeneration and loss. J Neurol Sci, 2005. 233(1-2): p. 183-98.
9

16.

Preische, O., et al., Serum neurofilament dynamics predicts neurodegeneration and
clinical progression in presymptomatic Alzheimer's disease. Nat Med, 2019. 25(2): p.
277-283.

17.

Brureau, A., et al., NF-L in cerebrospinal fluid and serum is a biomarker of neuronal
damage in an inducible mouse model of neurodegeneration. Neurobiol Dis, 2017. 104: p.
73-84.

18.

Zhou, W., et al., Plasma neurofilament light chain levels in Alzheimer's disease. Neurosci
Lett, 2017. 650: p. 60-64.

19.

Carneiro, P., S. Morais, and M. do Carmo Pereira, Biosensors on the road to early
diagnostic and surveillance of Alzheimer's disease. Talanta, 2020. 211: p. 120700.

20.

Li, W.W., et al., Association of Polygenic Risk Score with Age at Onset and
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort. Neurosci
Bull, 2020.

21.

Patel, H., et al., Working Towards a Blood-Derived Gene Expression Biomarker Specific
for Alzheimer's Disease. J Alzheimers Dis, 2020.

22.

Gonzalez Murcia, J.D., et al., Assessment of TREM2 rs75932628 association with
Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiol
Aging, 2013. 34(12): p. 2889.e11-3.

23.

Ridge, P.G., et al., Linkage, whole genome sequence, and biological data implicate
variants in RAB10 in Alzheimer's disease resilience. Genome Med, 2017. 9(1): p. 100.

24.

Wang, L.S., et al., Rarity of the Alzheimer disease-protective APP A673T variant in the
United States. JAMA Neurol, 2015. 72(2): p. 209-16.

25.

Suzuki, N., et al., Characterization of circulating DNA in healthy human plasma. Clin
Chim Acta, 2008. 387(1-2): p. 55-8.

26.

van der Vaart, M. and P.J. Pretorius, Circulating DNA. Its origin and fluctuation. Ann N
Y Acad Sci, 2008. 1137: p. 18-26.

27.

Diehl, F., et al., Detection and quantification of mutations in the plasma of patients with
colorectal tumors. Proc Natl Acad Sci U S A, 2005. 102(45): p. 16368-73.

28.

Diehl, F., et al., Circulating mutant DNA to assess tumor dynamics. Nat Med, 2008.
14(9): p. 985-90.

29.

Thierry, A.R., et al., Origin and quantification of circulating DNA in mice with human
colorectal cancer xenografts. Nucleic Acids Res, 2010. 38(18): p. 6159-75.

30.

Jiang, X., et al., Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung
Cancer Patients for Next-Generation Sequencing. Biopreserv Biobank, 2020.

31.

Nandi, K., et al., Cell free DNA: revolution in molecular diagnostics - the journey so far.
Horm Mol Biol Clin Investig, 2020.

10

32.

Zhou, Q., et al., Cell-free DNA analysis reveals POLR1D-mediated resistance to
bevacizumab in colorectal cancer. Genome Med, 2020. 12(1): p. 20.

33.

Brynychova, I., et al., Immunoregulatory properties of cell-free DNA in plasma of celiac
disease patients - A pilot study. Autoimmunity, 2019. 52(2): p. 88-94.

34.

Duvvuri, B. and C. Lood, Cell-Free DNA as a Biomarker in Autoimmune Rheumatic
Diseases. Front Immunol, 2019. 10: p. 502.

35.

Francis, G. and S. Stein, Circulating Cell-Free Tumour DNA in the Management of
Cancer. Int J Mol Sci, 2015. 16(6): p. 14122-42.

36.

Ramakrishna, S. and R.S. Muddashetty, Emerging Role of microRNAs in Dementia. J
Mol Biol, 2019. 431(9): p. 1743-1762.

37.

Swarbrick, S., et al., Systematic Review of miRNA as Biomarkers in Alzheimer's Disease.
Mol Neurobiol, 2019. 56(9): p. 6156-6167.

38.

Hosaka, T., et al., Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral
Sclerosis and Other Neurodegenerative Diseases. Int J Mol Sci, 2019. 20(13).

39.

Starhof, C., et al., The biomarker potential of cell-free microRNA from cerebrospinal
fluid in Parkinsonian Syndromes. Mov Disord, 2019. 34(2): p. 246-254.

40.

Lowes, H., et al., Cell-free mitochondrial DNA in progressive multiple sclerosis.
Mitochondrion, 2019. 46: p. 307-312.

41.

Calsolaro, V. and P. Edison, Neuroinflammation in Alzheimer's disease: Current
evidence and future directions. Alzheimers Dement, 2016. 12(6): p. 719-32.

42.

Baird, A., et al., Injury, inflammation and the emergence of human-specific genes.
Wound Repair Regen, 2016. 24(3): p. 602-6.

43.

Cai, Z., M.D. Hussain, and L.J. Yan, Microglia, neuroinflammation, and beta-amyloid
protein in Alzheimer's disease. Int J Neurosci, 2014. 124(5): p. 307-21.

44.

Heneka, M.T., et al., Neuroinflammation in Alzheimer's disease. Lancet Neurol, 2015.
14(4): p. 388-405.

45.

Liu, C., et al., Neuroinflammation in Alzheimer's disease: chemokines produced by
astrocytes and chemokine receptors. Int J Clin Exp Pathol, 2014. 7(12): p. 8342-55.

46.

Ma, W.P., X. Zhang, and Q. Wu, Research Advances in the Neuroinflammation in
Alzheimer's Disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2017. 39(5): p. 715-720.

47.

Marioni, R.E., et al., GWAS on family history of Alzheimer's disease. Transl Psychiatry,
2018. 8(1): p. 99.

48.

Ruiz, A., et al., Follow-up of loci from the International Genomics of Alzheimer's Disease
Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry, 2014. 4: p.
e358.

49.

Naj, A.C. and G.D. Schellenberg, Genomic variants, genes, and pathways of Alzheimer's
disease: An overview. Am J Med Genet B Neuropsychiatr Genet, 2017. 174(1): p. 5-26.
11

50.

Sekar, S., et al., Alzheimer's disease is associated with altered expression of genes
involved in immune response and mitochondrial processes in astrocytes. Neurobiol
Aging, 2015. 36(2): p. 583-91.

51.

Griciuc, A., et al., Alzheimer's disease risk gene CD33 inhibits microglial uptake of
amyloid beta. Neuron, 2013. 78(4): p. 631-43.

52.

Karch, C.M. and A.M. Goate, Alzheimer's disease risk genes and mechanisms of disease
pathogenesis. Biol Psychiatry, 2015. 77(1): p. 43-51.

53.

Zhu, R., X. Liu, and Z. He, Association between CLU gene rs11136000 polymorphism
and Alzheimer's disease: an updated meta-analysis. Neurol Sci, 2018. 39(4): p. 679-689.

54.

Wei, C., et al., Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology
in a Transgenic Mouse Model of Alzheimer's Disease. Neurochem Res, 2016. 41(8): p.
1924-38.

55.

Ramanan, V.K. and A.J. Saykin, Pathways to neurodegeneration: mechanistic insights
from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J
Neurodegener Dis, 2013. 2(3): p. 145-75.

56.

Seripa, D., et al., Role of CLU, PICALM, and TNK1 Genotypes in Aging With and
Without Alzheimer's Disease. Mol Neurobiol, 2018. 55(5): p. 4333-4344.

57.

Wolf, S.A., H.W. Boddeke, and H. Kettenmann, Microglia in Physiology and Disease.
Annu Rev Physiol, 2017. 79: p. 619-643.

58.

Kettenmann, H., et al., Physiology of microglia. Physiol Rev, 2011. 91(2): p. 461-553.

59.

Ji, K., et al., Microglia actively regulate the number of functional synapses. PLoS One,
2013. 8(2): p. e56293.

60.

Parkhurst, C.N., et al., Microglia promote learning-dependent synapse formation through
brain-derived neurotrophic factor. Cell, 2013. 155(7): p. 1596-609.

61.

Latta, C.H., H.M. Brothers, and D.M. Wilcock, Neuroinflammation in Alzheimer's
disease; A source of heterogeneity and target for personalized therapy. Neuroscience,
2015. 302: p. 103-11.

62.

Paresce, D.M., R.N. Ghosh, and F.R. Maxfield, Microglial cells internalize aggregates of
the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron, 1996.
17(3): p. 553-65.

63.

Bamberger, M.E., et al., A cell surface receptor complex for fibrillar beta-amyloid
mediates microglial activation. J Neurosci, 2003. 23(7): p. 2665-74.

64.

Liu, Y., et al., LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid
peptide. Brain, 2005. 128(Pt 8): p. 1778-89.

65.

Stewart, C.R., et al., CD36 ligands promote sterile inflammation through assembly of a
Toll-like receptor 4 and 6 heterodimer. Nat Immunol, 2010. 11(2): p. 155-61.

12

66.

El Khoury, J.B., et al., CD36 mediates the innate host response to beta-amyloid. J Exp
Med, 2003. 197(12): p. 1657-66.

67.

Kauwe, J.S.K., et al., Genome-Wide Association Study of CSF Levels of 59 Alzheimer's
Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid
Processing and Inflammation. Plos Genetics, 2014. 10(10): p. 16.

68.

Sokolova, A., et al., Monocyte chemoattractant protein-1 plays a dominant role in the
chronic inflammation observed in Alzheimer's disease. Brain Pathol, 2009. 19(3): p. 3928.

69.

Semple, B.D., T. Kossmann, and M.C. Morganti-Kossmann, Role of chemokines in CNS
health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. Journal
of cerebral blood flow and metabolism : official journal of the International Society of
Cerebral Blood Flow and Metabolism, 2010. 30(3): p. 459-473.

70.

van Gassen, K.L., et al., The chemokine CCL2 modulates Ca2+ dynamics and
electrophysiological properties of cultured cerebellar Purkinje neurons. Eur J Neurosci,
2005. 21(11): p. 2949-57.

71.

Old, E.A. and M. Malcangio, Chemokine mediated neuron-glia communication and
aberrant signalling in neuropathic pain states. Curr Opin Pharmacol, 2012. 12(1): p. 6773.

72.

Rollins, B.J., Chemokines. Blood, 1997. 90(3): p. 909-28.

73.

Jarnagin, K., et al., Identification of surface residues of the monocyte chemotactic protein
1 that affect signaling through the receptor CCR2. Biochemistry, 1999. 38(49): p. 1616777.

74.

Paavola, C.D., et al., Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and
activates the MCP-1 receptor CCR2B. J Biol Chem, 1998. 273(50): p. 33157-65.

75.

Bose, S. and J. Cho, Role of chemokine CCL2 and its receptor CCR2 in
neurodegenerative diseases. Arch Pharm Res, 2013. 36(9): p. 1039-50.

76.

Westin, K., et al., CCL2 is associated with a faster rate of cognitive decline during early
stages of Alzheimer's disease. PLoS One, 2012. 7(1): p. e30525.

77.

Kiyota, T., et al., CCL2 accelerates microglia-mediated Abeta oligomer formation and
progression of neurocognitive dysfunction. PLoS One, 2009. 4(7): p. e6197.

78.

Hartlage-Rubsamen, M., et al., Isoglutaminyl cyclase contributes to CCL2-driven
neuroinflammation in Alzheimer's disease. Acta Neuropathol, 2015. 129(4): p. 565-83.

79.

Kiyota, T., et al., AAV1/2-mediated CNS gene delivery of dominant-negative CCL2
mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.
Mol Ther, 2009. 17(5): p. 803-9.

80.

McGeer, E.G. and P.L. McGeer, Neuroinflammation in Alzheimer's disease and mild
cognitive impairment: a field in its infancy. J Alzheimers Dis, 2010. 19(1): p. 355-61.

13

81.

Naert, G. and S. Rivest, CC chemokine receptor 2 deficiency aggravates cognitive
impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease.
J Neurosci, 2011. 31(16): p. 6208-20.

82.

Bachelerie, F., et al., New nomenclature for atypical chemokine receptors, in Nat
Immunol. 2014: United States. p. 207-8.

83.

Bachelerie, F., et al., International Union of Basic and Clinical Pharmacology.
[corrected]. LXXXIX. Update on the extended family of chemokine receptors and
introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev, 2014.
66(1): p. 1-79.

84.

Hewit, K.D., et al., The N-terminal region of the atypical chemokine receptor ACKR2 is a
key determinant of ligand binding. J Biol Chem, 2014. 289(18): p. 12330-42.

85.

Sjoberg, E., et al., A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in
Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer. Clin Cancer Res,
2019. 25(12): p. 3702-3717.

86.

Nibbs, R.J. and G.J. Graham, Immune regulation by atypical chemokine receptors. Nat
Rev Immunol, 2013. 13(11): p. 815-29.

87.

Qi, Z., et al., Identification and expression analysis of an atypical chemokine receptor-2
(ACKR2)/CC chemokine binding protein-2 (CCBP2) in rainbow trout (Oncorhynchus
mykiss). Fish Shellfish Immunol, 2015. 44(2): p. 389-98.

88.

Neil, S.J., et al., The promiscuous CC chemokine receptor D6 is a functional coreceptor
for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on
astrocytes. J Virol, 2005. 79(15): p. 9618-24.

89.

Salvi, V., et al., Role of Atypical Chemokine Receptors in Microglial Activation and
Polarization. Front Aging Neurosci, 2017. 9: p. 148.

90.

Woodcock, T.M., et al., The scavenging chemokine receptor ACKR2 has a significant
impact on acute mortality rate and early lesion development after traumatic brain injury.
PLoS One, 2017. 12(11): p. e0188305.

91.

Crosslin, D.R., et al., Genetic variation associated with circulating monocyte count in the
eMERGE Network. Hum Mol Genet, 2013. 22(10): p. 2119-27.

92.

Fioravante, M., et al., Hypothalamic expression of the atypical chemokine receptor
ACKR2 is involved in the systemic regulation of glucose tolerance. Biochim Biophys
Acta Mol Basis Dis, 2019. 1865(6): p. 1126-1137.

93.

Li, D.D., et al., Effect of functional genetic variants in chemokine decoy receptors on the
recurrence risk of breast cancer. Cancer Med, 2018. 7(11): p. 5497-5504.

94.

Maho, A., et al., Mapping of the CCXCR1, CX3CR1, CCBP2 and CCR9 genes to the
CCR cluster within the 3p21.3 region of the human genome. Cytogenet Cell Genet, 1999.
87(3-4): p. 265-8.

14

95.

Mays, A.C., et al., Chemokine and Chemokine Receptor Profiles in Metastatic Salivary
Adenoid Cystic Carcinoma. Anticancer Res, 2016. 36(8): p. 4013-8.

96.

Stolp, J., et al., Intrinsic molecular factors cause aberrant expansion of the splenic
marginal zone B cell population in nonobese diabetic mice. J Immunol, 2013. 191(1): p.
97-109.

97.

Ahola-Olli, A.V., et al., Genome-wide Association Study Identifies 27 Loci Influencing
Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet, 2017.
100(1): p. 40-50.

98.

Crawford, D.C., et al., eMERGEing progress in genomics-the first seven years. Front
Genet, 2014. 5: p. 184.

99.

Traglia, M., et al., Cross-genetic determination of maternal and neonatal immune
mediators during pregnancy. Genome Med, 2018. 10(1): p. 67.

100.

Han, Z., et al., Functional annotation of Alzheimer's disease associated loci revealed by
GWASs. PLoS One, 2017. 12(6): p. e0179677.

101.

Appelberg, R., Macrophage inflammatory proteins MIP-1 and MIP-2 are involved in T
cell-mediated neutrophil recruitment. J Leukoc Biol, 1992. 52(3): p. 303-6.

102.

Oliveira, S.H., et al., Increased responsiveness of murine eosinophils to MIP-1beta
(CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8. J
Leukoc Biol, 2002. 71(6): p. 1019-25.

103.

Uguccioni, M., et al., Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3,
RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol, 1995.
25(1): p. 64-8.

104.

Farouk, S., et al., Bone marrow derived-mesenchymal stem cells downregulate IL17A
dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis. PLoS One,
2018. 13(10): p. e0206130.

105.

Aliberti, J.C., et al., beta-Chemokines enhance parasite uptake and promote nitric oxidedependent microbiostatic activity in murine inflammatory macrophages infected with
Trypanosoma cruzi. Infect Immun, 1999. 67(9): p. 4819-26.

106.

El-Asmar, L., et al., Evidence for negative binding cooperativity within CCR5-CCR2b
heterodimers. Mol Pharmacol, 2005. 67(2): p. 460-9.

107.

Trzaskowski, B., et al., Action of molecular switches in GPCRs--theoretical and
experimental studies. Curr Med Chem, 2012. 19(8): p. 1090-109.

108.

Lewis, N.D., et al., CCR1 plays a critical role in modulating pain through hematopoietic
and non-hematopoietic cells. PLoS One, 2014. 9(8): p. e105883.

109.

Minagar, A., et al., The role of macrophage/microglia and astrocytes in the pathogenesis
of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple
sclerosis. J Neurol Sci, 2002. 202(1-2): p. 13-23.

15

110.

Xia, M.Q., et al., Immunohistochemical study of the beta-chemokine receptors CCR3 and
CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol, 1998.
153(1): p. 31-7.

111.

Zhu, M., et al., Age-related brain expression and regulation of the chemokine
CCL4/MIP-1beta in APP/PS1 double-transgenic mice. J Neuropathol Exp Neurol, 2014.
73(4): p. 362-74.

112.

Jorda, A., et al., Changes in Chemokines and Chemokine Receptors Expression in a
Mouse Model of Alzheimer's Disease. Int J Biol Sci, 2019. 15(2): p. 453-463.

113.

Verite, J., et al., Differential chemokine expression under the control of peripheral blood
mononuclear cells issued from Alzheimer's patients in a human blood brain barrier
model. PLoS One, 2018. 13(8): p. e0201232.

114.

Reyes, N., et al., Atypical chemokine receptor CCRL2 is overexpressed in prostate
cancer cells. J Biomed Res, 2017.

115.

Galligan, C.L., et al., Up-regulated expression and activation of the orphan chemokine
receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum, 2004. 50(6): p. 1806-14.

116.

Migeotte, I., et al., Distribution and regulation of expression of the putative human
chemokine receptor HCR in leukocyte populations. Eur J Immunol, 2002. 32(2): p. 494501.

117.

Patel, L., et al., Expression and functional analysis of chemokine receptors in human
peripheral blood leukocyte populations. Cytokine, 2001. 14(1): p. 27-36.

118.

Hartmann, T.N., et al., Human B cells express the orphan chemokine receptor CRAM-A/B
in a maturation-stage-dependent and CCL5-modulated manner. Immunology, 2008.
125(2): p. 252-62.

119.

White, G.E., A.J. Iqbal, and D.R. Greaves, CC chemokine receptors and chronic
inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol
Rev, 2013. 65(1): p. 47-89.

120.

Zabel, B.A., et al., Mast cell-expressed orphan receptor CCRL2 binds chemerin and is
required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp
Med, 2008. 205(10): p. 2207-20.

121.

Catusse, J., et al., Role of the atypical chemoattractant receptor CRAM in regulating
CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol Cancer,
2010. 9: p. 297.

122.

Leick, M., et al., CCL19 is a specific ligand of the constitutively recycling atypical
human chemokine receptor CRAM-B. Immunology, 2010. 129(4): p. 536-46.

123.

Dean, M., M. Carrington, and S.J. O'Brien, Balanced polymorphism selected by genetic
versus infectious human disease. Annu Rev Genomics Hum Genet, 2002. 3: p. 263-92.

16

124.

Liang, Z., et al., Chemerin-induced macrophages pyroptosis in fetal brain tissue leads to
cognitive disorder in offspring of diabetic dams. J Neuroinflammation, 2019. 16(1): p.
226.

125.

Del Prete, A., et al., The atypical receptor CCRL2 is required for CXCR2-dependent
neutrophil recruitment and tissue damage. Blood, 2017. 130(10): p. 1223-1234.

126.

Zimny, S., et al., Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic
stellate cells and is positively associated with characteristics of non-alcoholic
steatohepatitis in mice and men. Exp Mol Pathol, 2017. 103(1): p. 1-8.

127.

Maiga, A., et al., Transcriptome analysis of G protein-coupled receptors in distinct
genetic subgroups of acute myeloid leukemia: identification of potential disease-specific
targets. Blood Cancer J, 2016. 6(6): p. e431.

128.

2016 Alzheimer's disease facts and figures. Alzheimers Dement, 2016. 12(4): p. 459-509.

17

Chapter 2: Cell-free single stranded DNA from CSF as possible biomarker for AD diagnosis

Josue D. Gonzalez Murcia1, Joshua J. Cassinat1, Meganne Ferrel1, Chiara Fenoglio2, Henrick
Zetterberg3,4,5,6, Robert A. Rissman7, Perry G. Ridge1, John S. K. Kauwe1

1

Brigham Young University, Department of Biology, Provo, Utah, 84602,USA

2

University of Milan, Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti,
20122 Milano, Italy
3

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The
Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
4

Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

5

Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London,
UK.
6

UK Dementia Research Institute at UCL, London, UK.

7

University of California San Diego School of Medicine, Department of Neuroscience, La Jolla,
California, 92093, USA

18

2.1 Abstract
Cerebrospinal fluid (CSF) contains critical biomarkers for Alzheimer’s disease (AD) such
as levels of amyloid beta (Aβ) phosphorylated-tau (p-tau), total-tau (t-tau), and neurofilament
light chain (NfL) peptides. The CSF levels of these peptide biomarkers are useful in determining
AD status in a patient, but data collection can be time consuming, technically difficult and
expensive. The purpose of this study is to evaluate cell free single stranded DNA (cfssDNA)
concentration isolated from CSF as a biomarker for diagnosis of AD. In collaboration with three
independent research facilities, we quantified cfssDNA from a total of 286 CSF samples (117
AD cases, 124 non-demented control, and 45 mild cognitive impairment (MCI)). Our results
indicate that cfssDNA concentration in CSF is significantly lower in AD cases than nondemented controls with an overall specificity of 0.782 and sensitivity score of 0.784 yielding an
AUC of 0.829. These cfssDNA AUC results are comparable to those reported in the literature for
Aβ, tau, and NfL. We conclude that the robust measurement characteristics of cfssDNA and its
performance in our studies make it an attractive candidate biomarker for AD.
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2.2 Introduction
Alzheimer’s disease (AD) is the primary cause of dementia without a cure in the elderly
population; however, earlier intervention of the disease improves patients’ cognitive longevity 1.
Several studies and efforts have contributed to the understanding of the genetic and molecular
biology architecture of this neurodegenerative disease. The neuropathology of AD is known for
synaptic and neuronal loss, gliosis, and peptide aggregation in the gray matter 2-4. AD is a
complex neurodegenerative disease that requires the involvement of experts across
multidisciplinary fields to provide a diagnosis. Current clinical diagnosis of AD takes place after
symptoms have started to manifest; however, AD pathology develops in an asymptomatic
fashion. Diagnosis of AD status considers family clinical history, symptoms, laboratory and
neuroimaging testing, cognitive impairment level, cognitive behavior, and biomarker levels 5.
Earlier diagnosis and detection of AD is vital to delaying cognitive decline in patients.
AD clinical symptoms are accompanied by the accumulation of the insoluble peptide
amyloid-beta (Aβ) in fibrillary plaques in the extracellular space of the brain 9. In addition,
neurofibrillary tangles composed of hyperphosphorylated tau protein form in the cytoplasm of
neurons 10. Aβ and tau protein levels in CSF have been extensively studied. They are used as
proxies for these pathological features and are often used as fluid biomarkers of AD 11-13.
However, the CSF levels of Aβ, p-tau and t-tau greatly differ between patients by age, stage of
disease, and genotype 7. This variability hinders a standardization of required thresholds of Aβ
and tau levels in CSF to determine AD status. Significance efforts to solve issues with
measurement variability and create consistency between labs are ongoing 7,14. Neurofilament
light chain (NfL) in CSF is another potential biomarker for AD 15,16. NfL is a major component
of the neuronal cytoskeleton, and soluble NfL can be detected in CSF and plasma 17. NfL lacks
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specificity as a biomarker for AD due to substantial overlap between AD, amnestic mild
cognitive impairment (aMCI), and mild cognitive impairment (MCI) cases 18. Several other CSF
and plasma analytes have been implicated by recent work and may prove to be useful biomarkers
pending further evaluation 19-24.
Cell-free DNA or circulating free DNA (cfDNA) primarily results from cells undergoing
apoptosis or necrosis as part of the physiological cell turnover 22,23. Another source of cfDNA is
direct release from macrophages and scavenger cells due to phagocytosis events of necrotic cells
24,25

. The outcome of these events leads to cfDNA in the form of fragmented DNA strands

ranging from 75 to 250 bp 25. CfDNA has been detected in blood, urine, stool, milk, and
bronchial lavages 26. Several studies have associated high levels of cfDNA with increased risk
for cancer 27-29 and autoimmune disorders 28,30,31. These associations suggest that cfDNA
quantification may serve as a biomarker for diagnosis, prognosis, and monitoring in cancer
patients 32. In AD, the quantification and biological property of cfDNA from CSF has not been
fully studied and the characterization of disease sensitivity and specificity has not yet been
determined. Extracellular RNAs have been investigated as possible biomarkers for AD but have
yielded inconsistent findings 33-35. Cell-free microRNAs have been initially studied as possible
biomarkers for Parkinson disease (PD) with promising results 36. Increased levels of cell-free
mitochondrial DNA have been associated with AD, PD, and progressive multiple sclerosis 37.
Together, these studies make a compelling case to further characterize cfDNA levels in CSF in
association with neurodegeneration, specifically AD.
To test this hypothesis, we have evaluated three independent cohorts to determine
whether cell-free single stranded DNA (cfssDNA) is an effective biomarker of AD status and
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severity and found lower concentration of cfssDNA from CSF in AD and MCI cases compared
to control group.

2.3 Results
2.3.1 CFS has normal cell count among all groups
Hemocytometer measurements failed to detect cells present in CSF in AD cases, control
and MCI groups. Microscopy cells count analysis determined the presence of cells ranging
between 1 to 5 cells/mL. This analysis determined cells count are consistent with expected cell
counts in CSF 38.

2.3.2 Cell-free double-stranded DNA and RNA measurements were below detection level in all
groups
Following Thermofisher Qubit manufacture protocols to measure double-stranded DNA
(dsDNA) and RNA isolated from CSF, we failed to detect signals of cell-free dsDNA material
above the minimal threshold from CSF. In addition, we failed to detect cell-free RNA
measurements above the minimal threshold isolated from CSF. These results were consistent
across AD cases, control, and MCI in all cohorts.

2.3.3 Subjects in AD and MCI groups have lower cfssDNA concentration than control group
2.3.3.1 Swedish cohort
ssDNA concentration was significantly lower in AD cases (µ = 74.43 ng/mL) than in
controls (µ = 95.6 ng/mL) (independent T-test, p-value = 0.0027) (table 2.2, supplemental figure
1A). The area under the curve (AUC) for the Receiver operating characteristic curve (ROC)
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analysis AD status prediction was 0.828 (specificity = 0.784; sensitivity = 0.781) using sex and
age as covariates (Supplemental figure 1B).

2.3.3.2 Italian Cohort
Concentration of ssDNA in AD cases were significantly lower (µ = 85.38 ng/mL) than in
control group (µ = 116.3 ng/mL) (Tukey’s multiple comparison test, p-value = 0.0373). MCI
group had a significantly lower concentration (µ = 58.86 ng/mL) than in controls (Tukey’s
multiple comparison test, p-value = <0.0001) and AD cases (Tukey’s multiple comparison test,
p-value = 0.0484) (table 2.2, supplemental figure 2A). AUC for the ROC analysis prediction AD
status was 0.827 (specificity = 0.644; sensitivity = 0.794) (Supplemental figure 2B) using sex as
covariate.

2.3.3.3 UCSD ADRC Cohort
ssDNA concentration was significantly lower in AD cases (µ = 66.55 ng/mL) than in
controls (µ = 92.93 ng/mL) (Tukey’s multiple comparison test, p-value = 0.0142). We failed to
detect a statistically difference between MCI cases (µ = 68.69 ng/mL) and controls (Tukey’s
multiple comparison test, p-value = 0.0716) (table 2.2, supplemental figure 3A). AUC for ROC
analysis prediction AD statues was 0.637 (specificity of 0.6; sensitivity of 0.644) (Supplemental
figure 3B).

2.3.3.4 Combined analysis
After standardizing ssDNA measurements from each cohort, AD cases group (µ = -9.06)
and MCI group (µ = -15.78) were significantly different from non-AD control group (µ = 14.28)
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(Tukey’s multiple comparison test, p-value = <0.0001) (table2.2, figure 1A). AUC of ROC
analysis prediction AD status was 0.829 (specificity = 0.782; sensitivity = 0.784) using sex and
age as covariates (Figure 1B).

2.3.3.5 Meta-analysis
Effect size was calculated in each cohort using AD and control group. The Italian cohort
reported an effect size of 0.75 (95% CI = 0.01 to 1.5; p-value 0.017). The Swedish cohort effect
size was 0.58 (95% CI = 0.2 to 0.97; p-value 0.048). The effect size of UCSD – ADRC cohort
was 0.57 (95% CI = 0.16 to 1.03; p-value 0.052). The overall effect size for the meta-analysis
was reported at 0.6 (95% CI = 0.34 to 0.86; p-value 0.038) (Table 3). In addition, the effect size
from the AD groups were compared with MCI groups in each cohort. The Italian cohort effect
size was 0.65 (95% CI = -0.01 to 1.3; p-value 0.041). The UCSD – ADRC cohort had an effect
size of 0.1 (95% CI = -0.49 to 0.5; p-value 0.64). After comparing these two cohorts, the overall
effect size was determined at 0.33 (95% CI = -0.2 to 0.87; p-value 0.13) (Table 2.3).

2.4 Discussion
These data provide evidence for cfssDNA as a biomarker for AD in three independent
cohorts. We observed ROC and AUC scores of 0.82 (specificity = 0.78; sensitivity = 0.78) in the
combined analysis. Published data using Ab and tau protein levels from CSF as possible
biomarkers for AD status report a sensitivity range from 0.75 to 0.94 and a specificity from 0.3
to 1.0 9,39-41. A recent study using NfL reported an AUC of 0.84 for AD diagnosis 42. Our
findings suggest that cfssDNA provides comparable performance to these other AD biomarkers
in discriminating AD from non-demented controls.
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Neurons, microglia, and astrocyte cells marked for apoptosis and gliosis are a hallmark of
neurodegenerative diseases 43,44. As these processes are likely to create cfDNA and other waste
products, our initial hypothesis was that AD cases would have a higher concentration of cfDNA
than control subjects. Surprisingly, we observed significantly lower levels of cfssDNA in AD
cases relative to controls in all three cohorts. While a complete answer to this surprising
observation is beyond the scope of this work, we speculate that increased microglia activity may
degrade cfDNA more completely in AD subjects or that decreased brain volume is resulting in
higher CSF volume and therefore lower concentrations of cfDNA. These questions could be
addressed in a mouse model of AD. A time course of cfssDNA levels in AD and healthy patients
would be also be useful for understanding this unanticipated association.

2.5 Methods
2.5.1 Cohorts
In collaboration with three independent research facilities, we quantified cfDNA material
from a total 286 CSF samples (117 AD cases, 124 non-demented control, and 45 MCI) (Table
2.1). CSF samples were extracted, handled, and diagnosed by each facility following their own
protocols to determine AD status.
Lumbar CSF samples from the University of California San Diego and the Alzheimer’s
Disease Research Center (ADRC) were obtained from volunteer participants with memory
problems. These participants have been followed over time while examining changes that occur
with age, life style and medications. CSF samples were collected and stored at -80oC pending
analysis. Patients were designated as AD or non-AD according to CSF biomarker levels using
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established cutoffs: total tau (T-tau) >400 ng/L, phospho-tau (P-tau) >60 ng/L and Ab 42 <450
ng/L.
Samples from the Swedish cohort were obtained in collaboration with the Institute of
Neuroscience & Physiology, The Sahlgrenska Academy at University of Gothenburg. Lumbar
CSF samples were obtained from patients who sought medical advice because of cognitive
impairment at Swedish memory clinics. All samples were collected by lumbar puncture into
polypropylene tubes, centrifuged at 2000 x g for 10 min and stored at -80oC pending analysis.
Patients were designated as AD or non-AD according to CSF biomarker levels using established
cutoffs: total tau (T-tau) >400 ng/L, phospho-tau (P-tau) >60 ng/L and Ab 42 <500 ng/L.
Lumbar CSF samples were obtained in collaboration with the University of Milan, Italy.
Samples were obtained from patients who sought medical attention because of memory loss and
cognitive impairment at the Department of Physiopathology and Medical Surgery at the Centro
Nazionali Trapianti, Italy. CSF samples were collected and stored at -80oC pending analysis.
Patients were designated as AD or non-AD according to CSF biomarker levels using established
cutoffs: total tau (T-tau) >400 ng/L, phospho-tau (P-tau) >60 ng/L and Ab 42 <450 ng/L.

2.5.2 Cell counting and microscopy
10 µL of CFS were mixed with 90 µL of prepared commassive blue. 10 µL of this
mixture were loaded in the hemocytometer for cell quantification under a light microscope.

2.5.3 DNA purification from CSF
DNA material was isolated from CSF using a QIAamp DNA Blood Mini Kit (cat #
51106) and following manufacture recommendations. Briefly, 200 µL of CSF was mixed by

26

vortexing with 20 µL of protease and 200 µL of lysis buffer and the mixture was incubated at 56
o

C for 10 minutes. Then 200 µL of 100% ethanol was added and mixed by vortexing. This lysed

mixture was passed to spin column and centrifuge at 8000 rpm. Then, the spin column was
washed with the provided buffer from the QIAamp kit. Finally, DNA material was collected
using 50 µL of elution buffer.

2.5.4 Cell free DNA and RNA measurement
Using Qubit Assay Technology and following Qubit manufacturer protocol, single
stranded DNA (ssDNA) (cat # Q10212), double stranded DNA (dsRNA) (cat # Q32850) and
RNA (cat # Q32852) kits were used to determine the presence of these materials in the samples.
5 µL of purified DNA material were used for quantification. All samples were screened in three
independent technical replications. The mean of the three technical replications per sample was
used to determine cell free DNA and RNA concentration in each sample. All measurements were
reported in ng/mL.

2.5.5 Statistical analyses
Statistical analyses were performed using the Prism 8 software (GraphPad Software, La
Jolla, CA, USA) and R ROCR and meta packages (R 3.5 El Capitan build). The difference of the
means between each group was analyzed using unpaired T-test and One-way ANOVA with
Tukey’s multiple comparison test. To determine the difference of the mean in between groups
combining all cohorts, values were standardized to a mean of zero. Receiver operating
characteristic curve (ROC), and area under the curve (AUC) were obtained using a
nonparametric nominal regression to determine AD status. Meta-analysis was done using effect
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size from the mean of the groups in each cohort. In this study, each experiment was performed
with 3 technical replicates. Results presented are representative of observed phenotypes and
analysis with p-values less than 0.05 were considered significant.
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Table 2.1 Cohorts and demographics.

Cohort

AD Cases

Control

MCI

Mean Age

SD of
mean age

Sex Ratio
(F)

Swedish

51

60

NA

72.35

10.91

37.3%

Italian

21

13

19

NA

NA

53%

UCSD ADRC

45

51

26

NA

NA

NA

Combined

117

124

45

NA

NA

NA
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Table 2.2 Cell-free single stranded DNA concentration results and analyzes.

Mean of Status

Difference of means

ROC

Cohort
Cases

Control

Difference

P-Value

AUC

Specificity

Sensitivity

Swedish

74.43

95.6

21.17

0.0027

0.82

0.784

0.781

Italian

85.38

116.3

30.89

0.0373

0.827

0.644

0.794

UCSD ADRC

66.55

92.93

26.39

0.0142

0.637

0.6

0.644

Combined

-9.06*

14.28*

23.34*

<0.0001

0.829

0.782

0.784

*Normalized data.
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Table 2.3 Cell-free single stranded DNA effect size and meta-analysis.

Cohort

AD vs Control

AD vs MCI

Effect size

95 % CI

Effect size

95% CI

P-value

Swedish

0.58

0.2 – 0.97

NA

NA

0.048

Italian

0.75

0.01 – 1.5

0.65

-0.01 – 1.3

0.017

UCSD ADRC

0.57

0.16 – 1.03

0.1

-0.49 – 0.5

0.052

Combined

0.6

0.34 – 0.86

0.33

-0.2 – 0.87

0.038
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Figure 2.1 Cell-free single stranded DNA (cfssDNA) is lower in Alzheimer’s disease (AD) and
mild cognitive impairment (MCI) cases than in non-demented controls.
A) After normalization and combination of cfssDNA levels in all cohorts, AD and MCI groups
have significantly less cfssDNA levels than non- demented control (**** = p-value <0.0001).
cfssDNA levels between AD and MCI are not significantly different. B) ROC analysis shows an
AUC of 0.829, specificity score of 0.782 and sensitivity score of 0.784.
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Supplemental Figure 2.1 Cell-free single stranded DNA (cfssDNA) is lower in Alzheimer’s
disease (AD) than non-demented controls in the Swedish cohort.
A) AD cases have significantly less cfssDNA levels than non- demented control (** = p-value =
0.027). cfssDNA levels between AD and MCI are not significantly different. B) ROC analysis
shows an AUC of 0.828, specificity score of 0.784 and sensitivity score of 0.781.
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Supplemental Figure 2.2 Cell-free single stranded DNA (cfssDNA) is lower in Alzheimer’s
disease (AD) than non-demented control group in the Italian cohort.
A) AD has significantly less cfssDNA than non-demented control group (* = p-value = 0.0373).
MCI groups have significantly less cfssDNA levels than non- demented control (**** = p-value
<0.0001). cfssDNA levels between AD and MCI are significantly different (* = p-value =
0.0484). B) ROC analysis shows an AUC of 0.827, specificity score of 0.644 and sensitivity
score of 0.794.
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Supplemental Figure 2.3 Cell-free single stranded DNA (cfssDNA) is lower in Alzheimer’s
disease (AD) than non-demented control group in the Italian cohort.
A) AD has significantly less cfssDNA than non-demented control group (* = p-value = 0.0142).
We failed to detect a significant difference between MCI group and non- demented control.
cfssDNA levels between AD and MCI are not significantly different. B) ROC analysis shows an
AUC of 0.637, specificity score of 0.60 and sensitivity score of 0.644
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3.1 Abstract
A recent genome-wide association study (GWAS) of 59 cerebrospinal fluid (CSF)
proteins with a connection to Alzheimer’s disease (AD) demonstrated an association between
increased levels of chemokine ligand 2 (CCL2) with an atypical chemokine receptor chemokinebinding protein 2 variant V41A (ACKR2-V41A; rs2228467). High levels of CCL2 are
associated with increased risk of AD development as well as other inflammatory diseases. In this
study we characterized the biological function of the ACKR2-V41A receptor compared to the
wild type allele by measuring its ligand binding affinity, CCL2 scavenging efficiency, and cell
activation sensitivity. We transfected Chinese hamster ovary cells with plasmids carrying wild
type ACKR2 (ACKR2-WT) or the mutant ACKR2-V41A receptor. Binding affinity assays
showed that ACKR2-V41A has a lower binding affinity for CCL2 and CCL4 than ACKR2-WT.
CCL2 scavenging results aligned with binding affinity assays, with ACKR2-V41A cells
scavenging CCL2 with a lower efficiency than ACKR2-WT. Cell activation assays also showed
that ACKR2-V41A cells had significantly lower receptor upregulation (β-Arrestin-dependent
signaling pathway) upon stimulation compared to ACKR2-WT cells. These findings provide
molecular and biological mechanistic insights into the GWAS association of ACKR2-V41A with
increased levels of CCL2 in CSF and possibly other chemokine ligands. Increased CCL2 levels
are associated with accelerated cognitive decline and increased the risk of AD. Understanding
how this atypical chemokine receptor allele increases serum markers of inflammation could lead
to novel therapeutic solutions for AD.
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3.2 Introduction
Inflammation is associated with increased risk of developing cancer, autoimmune
disorders, and neurodegenerative diseases such as Alzheimer’s disease (AD) 34. Acute
inflammation plays an essential role in the normal response to tissue injury 35,36. This
inflammatory response initiates a cascade of cellular activation signals in innate immune cells
(e.g. macrophages, mast cells, and endothelial cells), resulting in increased production of
proinflammatory cytokines and chemokines 37-39. These cytokines and chemokines are essential
to the recruitment and activation of other cells in the innate and adaptive immune system. An
inappropriate response to inflammation or alterations in the production of these chemokines can
result in disease development.
AD is the most common neurodegenerative disorder and is the main cause of dementia in
the elderly population 1. Significant progress has been made towards understanding the genetic
architecture of AD. To date, 32 loci have been identified with common and rare alleles that
influence the risk of AD 2,40,41. AD is pathologically characterized by the accumulation of
amyloid beta (Ab) peptide forming insoluble aggregated plaques in the gray matter and is
thought to result in neurodegeneration and loss of memory function 38,39,135. However, the
characterization of biological mechanisms by which these rare variants and the accumulation of
Ab modulate risk for disease has proven to be extremely difficult, with only several of these
variants being experimentally characterized 2,23,43-49.
Recent analyses of quantitative AD endophenotypes in cerebrospinal fluid (CSF) has
identified a chemokine receptor variant that alters the risk and rate of progression of AD 60. This
genome-wide association study (GWAS) of 59 AD-related CSF analytes used two independent
datasets: the Knight Alzheimer’s Disease Research Center (ADRC) and Alzheimer’s Disease
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Neuroimaging Initiative (ADNI) 60. This study demonstrated an association between increased
levels of chemokine ligand 2 (CCL2) with atypical chemokine receptor chemokine-binding
protein 2 (ACKR2) variant V41A.
CCL2 is also known as monocyte chemotactic protein-1 (MCP-1) and is encoded by the
CCL2 gene located on chromosome 17q11.2-q12. CCL2 is a pro-inflammatory chemokine
involved in recruitment of immune cells from the blood to sites of inflammation via chemokine
gradients. CCL2 helps to control blood brain barrier migration of monocytes and dendritic cells
and aids in the differentiation and migration of macrophages 61. In the brain, CCL2 is mainly
secreted by astrocytes, microglia, and in low levels by endothelial cells 62. Upon an immune
response to infection, injury or inflammation, CCL2 is produced in the central nervous system
(CNS) 63. CCL2 interacts with chemokine receptor CCR2 which signals via a G couple
protein cascade. Upon CCR2 and CCL2 ligand interaction, a cascade of cell activation events
takes place [i.e. activation of protein kinase C (PKC), calmodulin-dependent protein kinase II
(CaMKII), PI3K, Akt, and ERK]. This activation cascade signals cell migration, cell survival,
transcription regulation, and release of pro-nociceptive molecules 64,65. Upon CCL2 binding to
a receptor, it induces a strong chemotactic response and mobilization of intracellular calcium
ions and synaptic network activity in the hippocampal neurons 66,67. High levels of CCL2 is a
risk factor in several neuroinflammatory and neurodegenerative brain diseases such as multiple
sclerosis, brain ischemia, traumatic brain damage, and AD 68. In AD mouse models, CCL2 is key
to inducing chronic inflammation and activation of immune cells, and secretion of other
chemokines 69. Overexpression of CCL2 retains activated microglia cells near the inflamed site
70

. This results in increased interactions of activated microglia with key features of AD: amyloid

plaques, plague aggregation, and cognitive decline 71-73. Inhibition or removal of CCL2 in AD
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mouse models revealed accelerated amyloid pathology formation 74. These studies demonstrate
that proper function and regulation of CCL2 is imperative to preserve brain innate immune
response homeostasis and cognitive function.
Atypical chemokine receptor 2 (ACKR2 75) is encoded by the ACKR2 gene located on
chromosome 3p21.3. ACKR2 is a seven transmembrane G-protein-coupled receptor containing
three intracellular loops and three extracellular loops 76. ACKR2 binds with the 14 inflammatory
chemokines of the CC family, including CCL2 and CCL4, but not CCL19 77. ACKR2 is an
atypical chemokine due to its lack of a canonical DRYLAIV motif in the second extracellular
loop. This lack of motif inhibits the ability of the receptor to signal the production of other
cytokines 76. Instead, ACKR2 recognizes inflammatory chemokines, scavenges them, and
upregulates the production of more ACKR2 receptor 78. ACKR2 plays an essential role in the
regulation of the inflammatory response by internalizing inflammatory chemokines, facilitating
their destruction when the cellular endosome fuses with an acidic lysosome. The chemokine-free
ACKR2 receptor is then recycled back to the cell surface and can scavenge additional
inflammatory chemokines 79. ACKR2 is mainly expressed on leukocytes, including dendritic
cells, monocytes, macrophages, and innate-like B cells 80. In the central nervous system (CNS)
ACKR2 is mainly expressed in microglia and astrocyte cells 81-83. Nonsynonymous mutations
mapped to the ACKR2 gene have been associated with increased risk for breast cancer, testicular
leukemia, CD45 deficiency, glucose intolerance and inhibit leukocyte type differentiations and
monocyte counts 84-89.
The ACKR2-V41A allele (rs2228467) is associated with altered chemokine levels in the
CSF and bloodstream. A 2017 study with 8,293 Finn participants identified increased levels of
the chemokine eotaxin (a potent eosinophil attractant) associated with rs2228467 and increased
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risk of developing Crohn’s disease, multiple sclerosis, and ulcerative colitis 90. In a different
study involving over 11,000 subjects from the electronic Medical Records and Genomics
Network (eMERGE), rs2228467 was associated with increased coronary heart disease and a
higher monocyte count in the blood stream 84,91. Rs2228467 was also identified as an increased
risk factor for developmental disorders following the analysis of over 700 mother-infant pair
mid-gestational serum and neonatal bloodspots 92. Another 2017 study using the National Human
Genome Research Institution (NHGRI) dataset found that rs2228467 is associated with increased
AD risk 93. Together these studies make a compelling case for the biological characterization of
ACKR2-V41A. Here we provide the molecular and biological characterization of ACKR2-V41A
and show that it has decreased binding affinity, scavenging efficiency, and receptor upregulation
(β-Arrestin-dependent signaling pathway) for CCL2. These results provide insights into the
previously reported association of ACKR2-V41A with AD risk, rate of cognitive decline, and
serum markers of inflammation which could lead to novel therapeutic solutions for AD.

3.3 Results
3.3.1 ACKR2-V41A has similar predicted protein structure compared to wild type
ACKR2-V41A differs from wild type by a single amino acid located at the chemokine
binding site of ACKR2. V41A is specifically located in the first of three extracellular loops.
Predicted protein folding models were generated and ACKR2-WT and ACKR2-V41A were
superimposed to check for differences in folding and hydrophilicity. There was no observed
difference in predicted protein structure folding (Figures 1A and 1B).
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3.3.2 ACKR2-V41A is predicted to have minor hydrophilicity changes compared to wild type
The single amino acid change at position 41 is predicted to have a slight decreased
hydrophilicity between ACKR2-WT and ACKR2-V41A (Figures 1C and 1D). Despite a lack of
predicted folding and a minor hydrophilicity difference, this variant was predicted to have a
biological effect. Annotation analysis with RegulomeDB gave this nonsynonymous mutation a
score of 5/6. PolyPhen-2 predicted this variant to be probably damaging with a score of 0.958
(sensitivity: 0.78; specificity: 0.95). These predictor tools - Chimera, RegulomeDB and
PolyPhen-2 all predicted that the ACKR2-V41A variant causes a biological change with
functional consequences.

3.3.3 ACKR2-V41A and ACKR2-WT have similar receptor expression levels
CHO-k1 cells were transfected with ACKR2-WT or ACKR2-V41A and were grown in
selective media for a week before transfection positive cells were enriched using beads and
magnetic columns. The enriched CHO-k1 ACKR2-WT or ACKR2-V41A cell populations had
similar percentages of receptor positive cells (Figure 2A) and receptor expression levels (Figure
2B). T-test analysis (n = 5) failed to detect a significant difference between the percentage of
cells expressing ACKR2 WT or ACKR2-V41A at the cell surface. Indicating the transfection
efficiency between cell populations ACKR2-WT and ACKR2-V41A are not different.

3.3.4 ACKR2-V41A has decreased binding affinity for CCL2 compared to ACKR2-WT
The binding affinity of ACKR2-WT and ACKR2-V41A for CCL2 was measured in both
a direct binding and a competition assay. In the direct binding assay, the percentage of CCL2
binding to ACKR2-WT and ACKR2-V41A was determined by measuring the levels of
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Alexa463-congated CCL2 divided by the ACKR2 receptor levels. Analysis of 5 independent
runs revealed that ACKR2-V41A has a significantly lower binding affinity than ACKR2-WT
(Figure 3A; two tailed T test, p-value 0.0071). The ratio between percentage of CCL2 bound to
the receptor over percentage of chemokine receptor expression is lower in cells with ACKR2V41A (µ=64.16) than cells expressing ACKR2-WT (µ=79.12). These affinity differences were
consistent in 3 independent runs using a titration of conjugated chemokine ligand CCL2 starting
at 50 nM and reaching saturation for ACKR2-WT and V41A variant at 1200 nM (Figure 3B).
Non-linear analysis showed that ACKR2-V41A has a 1.5-fold higher equilibrium dissociation
constant (Kd = 103.4 nM) than ACKR2-WT (Kd = 67.68 nM) (Figure 3B). A similar method
was followed to observe if CCL19 was capable to interact with either ACKR2-WT or ACKR2V41A; however, there was no detectable interaction (Supplemental figure 1).
A competition assay was also performed to test if the unconjugated chemokine ligand
CCL2 was able to interfere with binding of an anti-ACKR2 antibody. Analysis of 5 independent
runs showed a significant difference between chemokine receptor ACKR2-WT and ACKR2V41A (two-tailed T test, p-value 0.0153). ACKR2-V41A expressing cells bound to significantly
lower levels of CCL2, allowing conjugated ab-ACKR2 to bind at a higher percentage (µ=88.5)
than ACKR2-WT (µ=66.18). Quantification of levels of unconjugated CCL2 blocking the antiACKR2 antibody show that ACKR2-V41A (11.5%) binds with significantly lower affinity to
CCL2 than ACKR2-WT (33.82%) (Supplemental figure 2).

3.3.5 ACKR2-V41A has decreased binding affinity for CCL4 compared to ACKR2-WT
The binding affinity of ACKR2-WT and ACKR2-V41A for CCL4 was measured in a
competition assay using an unconjugated CCL4 ligand to block the ACKR2 antibody. This
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competition analysis aligned with the CCL2 binding results with CCL4 blocked at a statistically
lower percentage by ACKR2-V41A (9.74%) than ACKR2-WT (26.0%) (Figure 4A; two-tail T
test, p-value 0.0310). These binding affinity results were consistent in 3 independent runs using a
titration of unconjugated CCL4 starting at 100 nM and reaching saturation for ACKR2-WT at
1000 nM (Figure 4B). Under this circumstances, ACKR2-V41A did not reach full saturation.
Non-linear analysis showed that ACKR2-V41A has a 3.4-fold higher Kd value (2033 nM) than
ACKR2-WT (600.2 nM).

3.3.6 ACKR2-V41A has decreased CCL2 scavenging efficiency compared to wild type
One of the main roles of the atypical chemokine receptor ACKR2 is to scavenge CCL2.
To determine scavenging efficiency, we incubated ACKR2-WT and ACKR2-V41A expressing
cells with CCL2 and measured levels of CCL2 in the supernatant over the course of 72 hours.
ACKR2-V41A cells scavenged CCL2 at a significantly lower efficiency rate than cells
expressing ACKR2-WT (Figure 5A; two tailed T test, p-value 0.0097). There is a significant
difference in scavenging efficiency between ACKR2-WT and ACKR2-V41A starting at the 18
hours time point until the last measurement at 72 hours (Figure 5B and 5C; two tailed T test, pvalue <0.0001 at 18, 24, 48, and 72 hours). ACKR2-WT has an IC50 of 18.19 hours, illustrating
that the WT receptor scavenges CCL2 2-times more efficiently than ACKR2-V41A, which has
an IC50 of 36.83 hours (Figure 5B; non-linear regression analysis). The increase in CCL2 levels
in the CHO-empty and media wells is likely due to evaporation over the course of 80 hours.
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3.3.7 ACKR2-V41A has decreased receptor upregulation compared to wild type
An increase in receptor recycling and ACKR2 receptor expression levels on the cell
surface is stimulated by the presence of a chemokine ligand capable of activating the receptor 55.
ACKR2-WT and ACKR2-V41A cell surface receptor levels were monitored for 72 hours after
the CCL2 chemokine was added to the supernatant. In this assay, cells expressing ACKR-WT or
ACKR2-V41A started with similar expression levels and maintained similar levels for 6 hours,
but from the 18 hours to the 72 hour time points ACKR2-V41A had significantly lower levels of
receptor expression (Figure 6A; two tailed T test, p-value 0.0045 and Figure 6B; two tailed T
test, p-value <0.01).

3.3.8 ACRK2-V41A has a lower expression of phosphorylated cofilin compared to wild type
To confirm that the ACKR2 receptor upregulation differences were dependent on the βArrestin-dependent signaling pathway, we measured cofilin phosphorylation. Cofilin part of the
β-Arrestin-dependent signaling pathway and is critical to the regulation of chemokine activation,
recycling, and production of the ACKR2 receptor. CHO-k1 cells expressing either ACKR2-WT
or ACKR2-V41A receptor were examined via western blot to determine the levels of
phosphorylated cofilin (p-cofilin) induced by CCL2. Upon activation of the receptors with
chemokine ligand CCL2, cells expressing ACKR2-V41A receptor had significantly lower pcofilin levels than cells expressing ACKR2-WT (Figure 7; two tailed T test, p-value 0.0137).

3.3.9 ACKR2-V41A has decreased activation sensitivity compared to wild type
CHO-k1 cells expressing either ACKR2-WT or the ACKR2-V41A chemokine receptor
activation profiles were also examined using live-cell calcium (Ca2+) imaging. Upon activating
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the receptor with chemokine CCL2, cells expressing the ACKR2-V41A receptor have
significantly lower levels of calcium signaling starting 4 minutes after CCL2 activation when
compared to CCBP-WT (Supplemental figure 3A; two tailed T test, p-value 0.0052). Analysis of
the area under the curve from minute 1 (addition of CCL2) to minute 5 (end time point) showed
that ACKR2-V41A cells have significantly lower levels of calcium signaling after CCL2
activation compared to ACKR2-WT (Supplemental Figure 3B; two tailed T test, p-value 0.008).

3.4 Discussion
We have identified direct biological effects of the ACKR2-V41A variant (rs2228467)
and a possible mechanism for increased levels of CCL2 in the CSF. ACKR2-V41A has lower
CCL2 binding affinity, CCL2 scavenging efficiency, and CCL2 induced ACKR2 receptor
upregulation. As proposed in the original GWAS analysis60, increased CSF CCL2 levels may
be due to decreased binding affinity of ACKR2-V41A for CCL2. Thus, we found that the
ACKR2-V41A variant also has altered binding to the chemokine CCL4, and an important area
to address in future studies will be how its binding is altered to all 12 of its known ligands.
Chimera protein predictor software and Regulomedb predicted that the amino acid
change from the hydrophobic valine to the less hydrophobic alanine was sufficient to change
biological function. In this study, we demonstrated that variant V41A, located at the first
extracellular loop and binding site, reduces the binding affinity of receptor ACKR2 with
CCL2 and CCL4 ligands. We suspect that same behavior will be observed if the binding
affinity of this variant is tested with the remaining 12 chemokine ligands known to interact
with it. In addition, ACKR2-WT and ACKR2-V41A did not noticeably improve binding for
the chemokine ligand CCL19. This ligand is one of the chemokines from the CC family that
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does not interact with ACKR2 receptor. Thus, in this case the V41A variant did not enable the
ACKR2 receptor to interact with a new chemokine ligand.
This altered ability of ACKR2 to bind CCL2 resulted in decreased CCL2 scavenging
activity and lower levels of receptor on the cell surface. ACKR2-V41A lost its scavenging
efficiency over time (after 18 hours of saturating the system with 100pg/ml of CCL2) and also
has decreased levels of the ACKR2 receptor at the cell surface over time (starting at 18 hours
after the cells were stimulated with 100pg/ml of CCL2) compared to wild type. We found that
ACKR2-V41A is 2-fold less efficient at scavenging CCL2, resulting in the maintenance of
this inflammatory chemokine signal for a longer time than wild type. These results suggest
that binding affinity and receptor levels are key to regulating levels of pro-inflammatory
chemokines such as CCL2.
ACKR2 is an atypical chemokine receptor and lacks the signaling motif to initiate the
production of other chemokine and cell migration. ACKR2 stimulation by CCL2 activates the
β-Arrestin-dependent signaling pathway cofilin pathway [Rac1-p21-activated kinase 1
(PACK1)-LIM kinase 1 (LIMK1) cascade] and ACKR2 can send an intracellular signal to
upregulate surface receptor levels 78,136,137. Here we report that after CCL2 activation, pcofilin expression levels were reduced in cells with the ACKR2-V41A receptor compared to
wild type. This result aligns with the assay examining ACKR2 receptor levels after CCL2
stimulation over a 72 hours period. Low levels of p-cofilin in ACKR2-V41A cells could
explain the low level of ACKR2 quantified at the cell surface and the decreased CCL2
scavenging activity. In addition, there are compelling studies showing that ACKR2 is capable
of Ca2+ mobilization upon stimulation with CCL2 in in HEK 293 cells 138 and neurons 63,139.
These studies align with our results and strengthen our proposed mechanism. Here we have
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shown a reduction of the biological capacity of the atypical chemokine ACKR2-V41A to
bind, scavenge, and be activated by CCL2. Additional impacts of the ACKR2-V41A allele
should also be examined in regard to the other 12 chemokines ACKR2 is known to bind
with77. Thus, alterations in chemokine levels caused by ACKR2-V41A have a powerful effect
on chemokine gradient homeostasis, inflammation, and increased risk to develop AD.
In the presence of Ab aggregation the expression and production of pro-inflammatory
related molecules, including CCL2, are elevated. In this context, it is known that high levels
of CCL2 expression and production trigger microgliosis, increase the APP/CCL2 ratio, and
increase Ab plaque aggregation. CCL2 could increase the rate of Ab deposition by
interference with clearance as well as increase expression of apolipoprotein E, a main
biomarker for AD pathogenesis and Ab deposition 70,140,141. Thus, regulation of CCL2 levels
has multiple effects on brain homeostasis and longevity. In this study, we observed significant
differences in the ability of ACKR2-V41A to bind and scavenge CCL2, potentially resulting
in higher levels of CCL2 at the injury site and maintenance of pro-inflammatory signaling and
monocyte recruitment, which may lead to increased Ab plaque aggregation and risk for AD.
GWAS researchers have identified thousands of genetic variants contributing to the rate of
development of complex human diseases; providing insights at the DNA level of how a single
nucleotide polymorphism (SNP) might cause changes in function at the biological and molecular
level. The characterization of biological mechanisms by which rare variants found in GWAS to
modulate risk for disease has proven to be extremely difficult. SNP characterization requires a
deeper understanding of how DNA changes might affect gene expression through transcription,
RNA splicing, ligand-receptor binding, protein function etc 142. Consequently, genetic variants
identified by GWAS have to be physiologically significant to conclusively identify their
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biological effects as proteins. In this study we provide the biological characterization of ACKR2V41A that was identified using a GWAS. We have provided insights into the mechanism by
which ACKR2-V41A with CCL2 alters the chemokine gradient homeostasis, increases
inflammation, and the alters risk for AD. Future efforts should focus understanding if and how
ACKR2-V41A impacts Ab production and aggregation and other biomarkers of AD in ADrelevant cell lines.

3.5 Methods
3.5.1 Chimera
ACKR2-WT and ACKR2-V41A chemokine receptor amino acids sequences were sent in
a FASTA format to the University of Michigan’s Zhang Lab LOMETS server. 3D models were
generated by collecting high-scoring structural templates from 11 locally-installed threading
programs (CEthreader, FFAS3D, HHpred, HHsearch, MUSTER, Neff-MUSTER, PPAS, PRC,
PROSPECT2, SP3, and SparksX) 143,144. These 11 models were compared to similar chemokine
receptors for accuracy. Using UCSF Chimera Software, the 3D models were oriented in space
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. We superimposed ACKR2-WT and ACKR2-V41A to check for differences in folding and

hydrophilicity. 3D images were produced using UCSF Chimera Software to highlight the
predicted chemokine receptor structure and hydrophobic interactions at amino acid position
41145.

3.5.2 Annotation
Annotation and prediction of the biological function of ACKR2-V41A variant was
determined using RegulomeDB and Polymorphims Phennotyping v2 (PolyPhen-2).
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RegulomeDB is a database that annotates variants with known and predicted regulatory elements
in human genome such as eQTL, transcription factor binding and transcription factor motif 146.
This predicter algorithm scores between 1 and 6 and any variant categorized between 1 and 5 is
predicted to have damaging biological function in the human genome. PolyPhen-2 is an
algorithm that predicts possible biological impact of an amino acid substitution in the human
genome 147. This algorithm classifies the biological impact of a variant from a damaging to a
tolerable variant.

3.5.3 Transformation and Transfection
Plasmid construct were ordered at Genscript, DNA sequences for ACKR2-WT and
ACKR2-V41A were inserted into vector pCMV6-AN-myc-DDK (ORIGENE, Cat #PS100016).
Transformation protocols were followed as recommended by the manufacturer. Briefly, plasmids
were transformed into DH5a cells, amplified, and purified using the ZymoPURE II Plasmid
Maxiprep kit (Cat #D4203). Plasmids were transfected into Chinese Hamster Ovary (CHO-k1
ATCC® CCL-61) cells using lipofectamine (ThermoFisher, Cat #15338100) and manufacture
recommendations were followed. Properly transfected cells were selected using the antibiotic
G418 sulfate (ThermoFisher, Cat #10131035). Transfected cells were grown in F12 media
(10 µg/ml penicillin, 10 µg/ml streptomycin; Gibco Cat #21127-022) with 10% FBS
(HYCLone Cat #SH30071.01). Cell media was changed every 48 to 72 hours depending on
cell confluency levels.
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3.5.4 Cell isolation
We tested the atypical chemokine receptor ACKR2-V41A function using CHO-k1
cells because they lack expression of the wild type ACKR2 receptor as well as other
competing human chemokine receptors. It is important to note that this cell type is absent in
the human brain and therefore our results should not be overinterpreted. After transfecting
CHO-k1 cells with plasmids carrying ACKR2-WT or ACKR2-V41A, cells were incubated until
they reached 80% confluency and prepared for cell sorting. Cells were stained for 30 minutes at
37°C with anti-human ACKR2 polyclonal IgG antibodies (ABNOVA Cat #H00001238-B02).
After two washes, cells were stained for 30 minutes at 4°C with anti-human IgG conjugated with
PE (Biolegend Cat #405307). Cells were then washed and isolated using anti-PE MicroBeads
from MACS Miltenyi Biotech (Cat #130-048-801) following manufacture recommendations.
After isolation, cells were incubated in F12 media until 80% confluency was reached.

3.5.5 Receptor expression
CHO-k1 cells transfected with ACKR2-WT or ACKR2-V41A were harvested when a 75
cm2 flask reached 80% cell confluency. 250,000 cells were resuspended in 300 µL of PBS-1%
BSA and placed in FACs tubes. To evaluate expression of the ACKR2 receptor, cells were
stained with anti-CD16/32 (Fc block) on ice for 20 minutes (eBioscience, Cat #14-0161-85).
After two washes, cells were stained for 30 minutes at 37°C with anti-human ACKR2 polyclonal
IgG antibodies, washed twice, and then stained for 30 minutes at 4°C with anti-human IgG
conjugated with PE. After two washes receptor expression was analyzed on a BD Accuri. In
addition, expression of the receptor at cell surface was monitor for 72 hours after CCL2 was
added to the growing media. Expression levels were obtained following the procedures above.
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3.5.6 Receptor binding
To determine CCL2 binding levels for ACKR2-WT and ACKR2-V41A, cells were
incubated with conjugated CCL2-AF647 (ALMAC, Cat# CAF-02-D-2) at 37°C for 45 minutes
at different concentrations ranging between 100 to 750 nM. After two washes receptor
expression was analyzed on a BD Accuri. To determine the levels of ACKR2-WT and ACKR2V41A receptor expression, cells were stained with anti-CD16/32 (Fc block) on ice for 20
minutes. After two washes, cells were stained for 30 minutes at 37°C with anti-human ACKR2
polyclonal IgG antibodies, washed twice, and then stained for 30 minutes at 4°C with antihuman IgG conjugated with PE. In the CCL2 competitive binding assay levels for ACKR2-WT
and ACKR2-V41A, cells were incubated with unconjugated CCL2 (PEPROTECH, Cat #30004100UG) at 37°C for 45 minutes. After two washes and an Fc block as described above, cells
were stained for 30 minutes at 37°C with anti-human ACKR2 polyclonal IgG antibodies, washed
twice, and then stained for 30 minutes at 4°C with anti-human IgG conjugated with PE. After
two washes levels of binding of the ACKR2 antibody was analyzed in BD Accuri.
CCL4 (PEPROTECH, Cat #300-.9) competition binding assay was performed following
the procedures above. Conjugated CCL9-AF647 (ALMAC, Cat #CAF-06-A-01) binding
analysis were completed using the same methods used for CCL2 biding assay.

3.5.7 ELISA
ACKR2-WT and ACKR2-V41A cells were seeded in a 6 well cell culture plate with
fresh F12 media with 10% FBS and 100 pg/mL of CCL2 added to each well. At varying time
points, 150 µL of media supernatant was extracted from each well to measure the remaining
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concentration of CCL2 using a CCL2 TMP sandwich ELISA kit (PeproTech, Cat #900-T31). 96
well ELISA microplates were coated overnight at room temperature with a monoclonal antibody
specific for human CCL2 (0.25 µg/mL in PBS). Plates were washed three time with 0.05%
tween diluted in PBS and then wells incubated with blocking buffer (PBS/1% BSA) for 2 hours
at room temperature. After three washes, samples and controls were added to the wells and
incubated for 2 hours at room temperature. After three washes plates were incubated for 1 hour
at room temperature with biotinylated anti-human CCL2 antibody (0.25 µg/mL) diluted in
blocking buffer. After three washes, plates were incubated with 100 µL of Streptavidin-HRP
conjugate (0.05 µg/mL) for 30 minutes at room temperature. Plates were washed three times and
100 µL of TMB substrate solution (hydroperoxide and chromogen tetramethylbenzidine) was
added for 20 minutes at room temperature in the dark. The reaction was stopped with 100 µL of
1M of hydrochloric acid. Optical density was determined using a micro plate reader set at 450
nm with a wavelength correction of 620 nm.

3.5.8 ACKR2 activation pathway
Levels of phosphorylated cofilin were obtained following methodology from previously
described research 137. Briefly, 300,000 CHO-k1 cells expressing either ACKR2-WT or ACKR2V41A were seeded in a well and serum-starved for 18 hours. Then, cells were stimulated with
100 nM of CCL2 (PEPROTECH, Cat #300-04100UG) and incubated at 37 °C in 5% CO2 for 30
minutes. Cells were harvest, lysed using RIPA lysing buffer (ThermoFisher, Cat #89900)
following manufacture recommendations. Lysed product was prepared for western blot assay.
Antibody for P-cofilin (Cells signaling, Cat #3313) was used to detect protein of interest.
ImageJ (ImageJ software, NIH) was used to analyze the intensity of bands corresponding to p57

cofilin. Data was normalized using cofilin (Cell signaling, Cat #5175). An independent T test
was performed to determine if p-cofilin levels differ between cell expressing ACKR2-WT and
ACKR2-V41A.

3.5.9 Calcium activation
Cells were seeded on a 8-chambered slide (Nunc, Cat #155411) and incubated
overnight in F12 media with 10% FBS at 37 °C in 5% CO2. The next day, cells were loaded
with 4 µM of Fura-2AM (Invitrogen, Cat #F1221) in Ringers solution (150 mM NaCl, 10 mM
glucose, 5 mM HEPES, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, pH 7.4) for 30 min at 37°C in
5% CO2. Cells were then washed once with Ringers solution and incubated for another
30 minutes at 37°C in Ringers solution. Calcium imaging was performed at room temperature
using an Olympus IX51 inverted microscope equipped with a xenon arc lamp. Fura-2AM
loaded CHO-k1 cells expressing receptor ACKR2-WT and ACKR2-V41A were excited using
340 nm and 380 nm excitation filters, and images of 340 nm, 380 nm, and transmitted light
was captured using a fluorescence microscope camera (Q Imaging Exi Blue) with a 20x
objective (N.A. 0.75) at 1.6-sec intervals. At the 1-min time point in each imaging protocol,
250 nM of recombinant Human CCL2 was added to stimulate Ca2+ flux 63. Ionomycin (1 µM
final concentration) was added at the 5-min time point as a positive control. 10–20
representative cells were selected as regions of interest in each frame, and F340:F380 ratios
were calculated and analyzed using CellSens software from Olympus. Each individual cell’s
fluorescence was normalized to its first recorded value according to the equation (F-Fo)/Fo,
where F is the fluorescence at the specific time point, and Fo is the fluorescence value at time
0 148,149 .
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3.5.10 Statistical Analysis
Statistical analyses were performed using the Prism 8 software (GraphPad Software, La
Jolla, CA, USA). Differences in binding affinity, CCL2 scavenging efficiency, and cell
activation sensitivity between ACKR2-V41A and ACKR2-WT were analyzed using an unpaired
T-test. Kd, EC50, and IC50 were calculated using non-linear analysis best fit test. Each
independent run contained a minimum of 3 replicates per sample and the mean of those
replicates were considered a single point of analysis. In this study, each experiment was
performed with 3 to 5 independent runs (9 to 15 replicates per sample). Results presented are
representative of observed phenotypes and analysis with P-values less than 0.05 were considered
significant.
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Figure 3.1 Model of ACKR2-V41A does not predict a change in protein folding and predicts minor
decrease in hydrophilicity.
There is no dramatic difference in predicted protein folding and and a minor decrease in
hydrophilicity between ACKR2-WT and ACKR2-V41A. A) Side by side ribbon view of
ACKR2-WT (blue and green) and ACKR2-V41A (gold and red) protein models. B) Overlay of
ACKR2-WT and ACKR2-V41A ribbon models highlighting the folding at amino acid position
41 (WT is green and V41A is red). C) Side by side ribbon structure of amino acid position 39-43
for ACKR2-WT and ACKR2-V41A (WT is green and V41A is red) D) View of hydrophobic
(red) and hydrophilic (blue) amino acids at amino acid positions 39-43 for the ACKR2-WT (left)
and ACKR2-V41A (right) chemokine binding site. Amino acid 41 is shown in the middle right
of both models.
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Figure 3.2 Atypical chemokine receptor ACKR2-V41A and ACKR2-WT have similar levels of
receptor expression on the cell surface.
A) There is no significant difference in the percent of positive cell for the atypical chemokine
receptors ACKR2-V41A and ACKR2-WT (n=5; ns = not significant) at the cell surface. B)
ACKR2-V41A and ACKR2-WT have similar cell expression levels (n=3).
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Figure 3.3 CCL2 binds with lower affinity to ACKR2-V41A compared to ACKR2-WT in ligand
binding assay.
A) ACKR2-WT and ACKR2-V41A transfected cells were incubated with conjugated antiACKR2 antibody and a separate tube of ACKR2-WT and ACKR2-V41A transfected cells were
incubated with conjugated CCL2. After normalizing the percentage of CCL2+ cells over
ACKR2+ cells, there is a significantly lower binding affinity between ACKR2-V41A than
ACKR2-WT for CCL2 (two tailed T test; p-value 0.0071) (n = 5; ** = p<0.01). B) The same
experiment was repeated using different concentrations of CCL2 ligand (ranging from 50 nM to
1200 nM). ACKR2-WT was saturated when 650 nM of CCL2 ligand was used (n=3) yielding a
1.5 lower Kd value (67.68 nM) than ACKR2-V41A (103.4 nM).
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Figure 3.4 CCL4 binds with lower affinity to ACKR2-V41A compared to ACKR2-WT in ligand
binding assay.
A) Cells were incubated with unconjugated CCL4 for 45 minutes at 37°C; then, conjugated antiACKR2 was added to determine levels of receptor binding inhibition by CCL4. ACKR2 bound
to CCL4 with lower affinity, resulting in higher ACKR2 receptor binding with the anti-ACKR2
antibody compared to ACKR2-WT. 100 minus the percentage of ACKR2+ cells were subtracted
to determine the percentage of CCL4 blockage. ACKR2-V41A (9.74%) was blocked at a
significantly lower percentage by CCL4 than ACKR2-WT (26.0%) (n=5; * = p<0.05). B) The
same experiment was repeated using different concentrations of CCL4 ligand (ranging from 100
nM to 1200 nM). ACKR2-WT was saturated at 1000 nM of CCL4 ligand (n=3) yielding a 3.4fold lower Kd value (600.2 nM) than ACKR2-V41A (2033 nM).
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Figure 3.5 ACKR2-V41A has a significantly lower scavenging efficiency for CCL2.
A) CCL2 scavenging efficiency measurements. CHO-k1 cells expressing ACKR2-WT and
ACKR2-V41A were incubated with an initial concentration of 100 pg/mL of CCL2. CCL2 levels
were measured over the course of 72 hours. Cells with atypical chemokine ACKR2-V41A
scavenged significantly lower levels of CCL2 compared to ACKR2-WT (two tailed T test, pvalue 0.0097) (n=5; **** = p<0.0001). B) ACKR2-V41A has a 2-fold higher IC50 value (36.83
hours) than ACKR2-WT (18.19 hours). C) Scavenging analysis by time point. At 6 hours
ACKR2-WT and ACKR2-V41A were scavenging at the same rate. After 18 hours, cells with
receptor ACKR2-V41A started scavenged CCL2 ligand at a significantly lower rate and this
continued up to 72 hours (n=5; **** = p<0.0001).
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Figure 3.6 ACKR2-V41A has a significantly lower expression upon CCL2 stimulus.
A) ACKR2-V41A and WT expression over 72 hours. CHO-k1 cells expressing ACKR2-WT and
ACKR2-V41A were incubated with an initial concentration of 100 pg/mL of CCL2. Receptor
expression was measured over the course of 72 hours. Cells with atypical chemokine ACKR2V41A responded significantly lower to the stimulus of CCL2 compared to ACKR2-WT (two
tailed T test, p-value 0.0045) (n=3; **=p<0.01). B) Receptor over time analysis by time point. At
6 hours mark ACKR2-WT and ACKR2-V41A were expressing the similar amount of receptor at
the cell surface. After 18 hours, cells with receptor ACKR2-V41A were expressed at a
significantly lower percentage and this continued up to 72 hours (n=3; **=p<0.01, *** =
p<0.001).
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Figure 3.7 ACKR2-V41A has lower levels of phosphorylated cofilin after activation with CCL2
ligand.
The G protein-dependent response of CHO-k1 cells with atypical chemokine ACKR2-WT and
ACKR2-V41A receptors were measured by presence of p-cofilin in either receptor. P-cofilin
levels were measured after activation with CCL2 for 30 minutes. Data was normalized using
cofilin. Cells expressing ACKR2-V41A had significantly lower p-cofilin than cells expressing
ACKR2-WT (n = 3, two tail T test, p-value 0.0137)
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Supplemental Figure 3.1 CCL19 does not interact with ACKR2 receptor.
Atypical chemokine receptors ACKR2-WT and ACKR2-V41A were compared in a binding
affinity assay with CCL19. ACKR2-WT and ACKR2-V41A transfected cells were incubated
with conjugated anti-ACKR2 antibody and a separate tube of ACKR2-WT and ACKR2-V41A
transfected cells were incubated with conjugated CCL19. After normalizing the percentage of
CCL19+ cells over ACKR2+ cells, we failed to detect interaction between CCL19 with ACKR2WT and ACKR2-V41A.
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Supplemental Figure 3.2 CCL2 binds with lower affinity to ACKR2-V41A in a competition
binding assay.
Atypical chemokine receptors ACKR2-WT and ACKR2-V41A were compared in a competition
binding assay. A. Cells were incubated with unconjugated CCL2 for 45 minutes at 37°C; then,
conjugated anti-ACKR2 was added to determine levels of receptor binding inhibition by CCL2.
ACKR2 bound to CCL2 with lower affinity, resulting in higher ACKR2 receptor binding with
the anti-ACKR2 antibody compared to ACKR2-WT (ACKR2-V41A µ=88.5; ACKR2-WT
µ=66.18; two-tailed T test; p-value 0.0153) (n=5; * = p<0.05). 100 minus the percentage of
ACKR2+ cells were subtracted to determine the percentage of CCL2 blockage. ACKR2-V41A
(µ=11.5) was blocked at a significantly lower percentage by CCL2 than ACKR2-WT (µ=33.82)
(n=5; * = p<0.05).
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Supplemental Figure 3.3 ACKR2-V41A has lower levels of calcium signaling after activation
with CCL2 ligand.
The calcium response of CHO-k1 cells with atypical chemokine ACKR2-WT and ACKR2V41A receptors were measured. A. Calcium levels were measured after activation with CCL2 at
the 1-minute time point. Cells expressing ACKR2-V41A had significantly lower Ca2+ influx than
cells expressing ACKR2-WT starting at the 4 minutes time point (two tail T test, p-value 0.0052)
(n=35; * = p<0.05). B. Area under the curved (AUC) analysis from minute 1 (CCL2 activation)
to minute 5 (assay end point) confirmed that ACKR2-V41A had significantly lower levels of
Ca2+ influx than ACKR2-WT (two tail T test, p-value 0.008) (n=35; ** = p<0.01).
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Supplemental Figure 3.4 Western blot cofilin and phosphorylated cofilin.
300,000 CHO-k1 cells expressing either ACKR2-WT or ACKR2-V41A were seeded in a 6-well
plates and serum-starved for 18 hours. Then, cells were stimulated with 100 nM of CCL2 and
incubated at 37 °C in 5% CO2 for 30 minutes. Cells were harvest, lysed using RIPA lysing
buffer following manufacture recommendations. Lysed product was prepared for western blot
assay. Two gels were run in parallel using the same lysed product samples. A. cofilin blot. B.
phosphorylated cofilin blot.
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4.1 Abstract
A recent genome-wide association study (GWAS) of 59 cerebrospinal fluid (CSF) proteins with
connection to Alzheimer’s disease (AD) demonstrated an association between decreased levels
of chemokine ligand 4 (CCL4) and an atypical chemokine receptor, C-C chemokine receptor-like
2 variant V180M (CCRL2-V180M). Low levels of CCL4 are associated with a decreased risk of
AD development as well as other inflammatory diseases. In this study, we characterized the
biological function of the CCRL2-V180M allele compared to the wild type allele in both CCRL2
receptor isoforms (CRAM-A and CRAM-B). Protein model analysis did not predict CCRL2V180M causing a structural change compared to CCRL2-WT protein, but it did predict changes
of hydrophilicity interactions between CCRL2-V180M and CCRL2-WT. Binding assays
revealed that CCRL2-V180M has a higher binding affinity for chemerin and CCL19 than
CCRL2-WT. Additionally CCRL2-V180M interactions with CCL19 demonstrates altered CCL4
secretion from leukocytes compared to wild type CCRL2. These findings provide molecular and
biological mechanistic insights into the GWAS association between CCRL2-V180M and
decreased levels of CCL4 in CSF. Decreased CCL4 levels are associated with less cognitive
decline and decreased risk for AD. These results provide a partial biological mechanism
explaining the mechanism behind a previously described biomarker for AD. Understanding how
this atypical chemokine receptor allele decreases serum markers of inflammation could lead to
novel therapeutic solutions for AD and other diseases.
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4.2 Author Summary
Alzheimer’s disease (AD) is a fatal neurodegenerative disease and the leading cause
of dementia in the elderly population. Research has shown that the innate immune system plays a
pivotal role in AD pathology development. A recent GWAS measured 59 analytes from
cerebrospinal fluid (CSF) with clear associations with AD. The atypical chemokine allele
variant, CCRL2-V180M, was associated with decreased levels of CCL4. In this study, we
characterize the biological function of the CCRL2-V180M receptor compared to the CCRL2-WT
receptor. Protein analyses predicted no structural changes; however, hydrophilicity interactions
were altered between CCRL2-V180M and CCRL2-WT. CCRL2-V180M has a lower binding
affinity for chemerin and CCL19. CCRL2-V180M interacting with CCL19 results in lower
CCL4 secretion from leukocytes. These findings provide mechanistic insights into the GWAS
association of CCRL2-V180M with decreased levels of CCL4 in CSF. Here we characterized
both isoforms of an allele associated with lower levels of CCL4 that is a potential protective
biomarker against AD development. Understanding how this atypical chemokine receptor allele
decreases serum markers of inflammation could lead to novel therapeutic solutions for AD and
other diseases.
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4.3 Introduction
Recent findings in Alzheimer’s disease (AD) genetics and biomarkers suggest a key role
of inflammation in AD pathology 1. Acute inflammation plays a key role in the normal response
to tissue injury 2,3. These responses initiate a cascade of cellular activation signals in innate
immune cells, which enhance the production of proinflammatory cytokines and chemokines 4-6.
Any deviation from normal production of chemokines in response to inflammation might result
in altering the risk of developing disease, such as AD.
AD is the primary cause of dementia in the elderly population 7. Several studies and
efforts have contributed to the understanding of the genetic and biological architecture of this
neurodegenerative disease. Currently 32 loci have been associated, both common and rare
variants across the human genome, as risk factors contributing to the development of AD 8-10.
However, it has been difficult to biologically characterize these associated rare variants and
find the mechanism by which they alter the hallmark biomarker amyloid beta (Ab) peptide
and its aggregation in the brain 5,6,11. Only a small number of these variants have been fully
biologically characterized 8,12-19.
Quantitative analysis of AD traits in cerebrospinal fluid (CSF) has identified a possible
interaction between atypical C-C motif chemokine receptor-like 2 (CCRL2) and chemokine
ligand 4 (CCL4) as a possible protective variant against AD development 20. This genome-wide
association study (GWAS) proposed that lower levels of CCL4 in CSF are associated with
CCRL2-V180M. CCL4, also known as macrophage inflammatory protein-1β (MIP-1-b)
activates cellular migration of eosinophils, neutrophils, lymphocytes, and monocytes 21-23. CCL4
induces the synthesis and release of pro-inflammatory cytokines such as IL-1, IL-6 and TNF
from fibroblasts and macrophages contributing to an inflammatory cytokine response 24,25. CCL4
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ligand in known to bind to C-C chemokine receptor type 5 (CCR5) 26,27 and C-C chemokine
receptor 1 (CCR1) facilitating trafficking of leukocytes to the inflammation site 28. In AD cell
and mouse models, CCL4 is predominantly expressed in activated subpopulations of astrocytes
and microglia 29,30. Several independent studies evaluating AD have demonstrated that CCL4
levels are elevated in AD animals and cell cultures models in response to brain inflammation 3133

. Together these studies suggest that CCL4 plays a role in the inflammatory response associated

with altering the development of AD.
CCRL2 also known as ACKR5, is an atypical chemokine receptor due to its lack of a
canonical DRYLAIV motif in the second extracellular loop, inhibiting the ability to signal 34.
CCRL2 is a seven transmembrane G protein-coupled receptor containing three intracellular and
three extracellular domains 35. CCRL2 is expressed in almost all human hematopoietic cells
including monocytes, macrophages, PMNs, T cells (CD4+ and CD8+), monocyte-derived iDCs,
NK cells, and CD34+ progenitor cells 36-38. CCRL2 has two isoforms known as CRAM-A and
CRAM-B; the CRAM-B isoform is 12 amino acids shorter 39. Both isoforms of CCRL2 are
reported to bind and concentrate chemerin facilitating activation and presentation to CMKLR1
on adjacent cells 40,41. It has been reported that CRAM-B interacts with CCL5 and CCL19 39,42,43,
however, it is unclear if CRAM-A has similar binding properties towards CCL19 as CRAM-B.
Genetic variants and downregulation of CCRL2 have been associated with elevating the risk to
develop cancer, autoimmunity, and metabolic diseases 44-50. These studies showing alterations in
binding affinity for chemerin and CCL19 make a strong case for the biological characterization
of CCRL2-V180M variant and its association with lower levels of chemokine ligand CCL4 in
CSF serving as protective variant against AD development. These discoveries could lead to
novel therapeutic solutions for AD and other immune diseases associated with CCRL2.
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4.4 Results
4.4.1 The CCRL2-V180M protein folding is predicted to be highly similar to CCRL2-WT.
CCRL2-V180M differs from wild type by a single amino acid located at the chemokine
binding site of CCRL2. V180M is specifically located in the second of three extracellular loops.
Predicted protein folding models were generated for CRAM-A and CRAM-B isoforms and were
superimposed on CCRL2-WT to identify differences in folding. There was no observed
difference in predicted protein structure folding for isoform CRAM-A (Figures 1A and 1B) or
CRAM-B (Figures 1C and 1D).

4.4.2 CCRL2-V180M is predicted to have minor hydrophilicity changes compared to the wild
type
The single amino acid change at position 180 is predicted to have a slight decrease in
hydrophilicity between CCRL2-WT and CCRL2-V180M in both CRAM-A and CRAM-B
isoforms (Figures 1E and 1F). Due to the observable changes of predicted folding and a minor
hydrophilicity difference, this variant was predicted to have a biological effect. Annotation
analysis with RegulomeDB gave this nonsynonymous mutation a score of 5/6. PolyPhen-2
predicted this variant is likely benign with a score of 0.095 (sensitivity: 0.93; specificity: 0.85).
These predictor tools—Chimera, RegulomeDB and PolyPhen-2—all concluded that the CCRL2V180M variant causes a biological change with functional consequences.

4.4.3 CCRL2-V180M and CCRL2-WT have similar receptor expression levels
CHO-k1 cells were transfected with CRAM-A-WT, CRAM-A-V180M, CRAM-B-WT,
or CRAM-B-V180M and were grown in selective media for a week before transfection positive
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cells were enriched using beads and magnetic columns. The enriched CHO-k1 CCRL2-WT and
CCRL2-V180M cell populations had similar percentages of receptor positive cells
(Supplemental figure 1A). T-test analysis (n = 3) failed to detect a significant difference between
the percentage of cells expressing CRAM-A and CRAM-B WT and those expressing the V180M
variant at the cell surface. Indicating that the transfection efficiency between cell populations is
not different.

4.4.4 CCRL2-V180M has increased binding affinity for chemerin compared to CCRL2-WT
The binding affinity of CCRL2-WT and CCRL2-V180M for chemerin, a known ligand,
was measured using both CRAM-A and CRAM-B isoforms. The percentage of chemerin binding
to the receptor was determined by measuring the levels of anti-human IgG bound to cell exposed
to a human-FC chain in chemerin divided by CCRL2 receptor level 41. For the CRAM-A
isoform, an analysis of five independent runs demonstrated that CCRL2-V180M binds at a
significantly higher level than CCRL2-WT (Figure 2A; two tailed T test, p-value 0.0376). The
ratio of chemerin bound to cells expressing CCRL2-V180M is higher (µ=77.50) than on cells
expressing receptor CCRL2-WT (µ=50.76). CRAM-B transfected cells showed similar results as
seen with CRAM-A. CCRL2-V180M has higher binding affinity ratio (µ=67.23) than CCRL2WT (µ=51.22) (Figure 2B two tailed T test, p-value 0.0491). These affinity differences were
performed in three independent runs using an unconjugated chemerin starting at 50 nM and
reaching saturation for CCRL2-WT and the V180M variant at 1500 nM in both isoforms
CRAM-A and CRAM-B (Figure 2C and 2D). Non-linear analysis showed that CRAM-AV180M has a 4.6-fold lower equilibrium dissociation constant (Kd = 96.60 nM) than CRAM-AWT (Kd = 444.3 nM) (Figure 2B). Unconjugated chemerin was measured starting at 50 nM and
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reaching saturation at 1000 nM for CRAM-B. V180M variant in CRAM-B has a 2.7-fold lower
Kd value (220.8 nM) compared with CRAM-B-WT (Kd = 598.3 nM) (Figure 2D).
A competition assay was performed to test if unconjugated chemokine was able to
interfere with the affinity of conjugated anti-CCRL2 in CRAM-A receptors. Analysis of five
independent runs showed chemerin displacing a higher percentage of anti-CCRL2 in cells
transfected with CCRL2-V180M (µ=42.26) than in cells expressing CCRL2-WT (µ=32.35)
(Supplemental figure 2; two tailed T test, p-value 0.0062).

4.4.5 CCRL2-V180M (CRAM-A) has increased binding affinity for CCL19 compared to wild type
The ratio of binding affinity of CCRL2-V180M and CCRL2-WT for chemokine ligand
CCL19 was measured in both CRAM-A and CRAM-B isoform. Cells expressing CRAM-AV180M receptor had higher binding affinity (µ=41.57) than cells expressing CRAM-A-WT
receptor (µ=29.12) (Figure 3A; two tailed T test, p-value 0.0162). We failed to detect a
significant difference of CCL19 binding in cells transfected with the CRAM-B isoform, CCRL2V180M (µ=25.47) and CCRL2-WT (µ=21.67) (Figure 3B; two tailed T test, p-value 0.4446).

4.4.6 CCRL2 does not interact to chemokine ligand CCL4
The binding interaction of CCRL2-V180M and CCRL2-WT with CCL4 was measured in
a competition assay in both CRAM-A and CRAM-B isoforms. We failed to detected a difference
in the percentage of CCRL2 blocked between cells incubated with chemerin only and chemerin
plus CCL4. in both isoforms and both WT and V180M receptors. These results were consistent
in three independent runs and across both isoforms (Figure 4A and 4B).
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4.4.7 CCRL2-V180M (CRAM-A) has similar scavenging properties for chemerin as CCRL2-WT
One of the key features of atypical chemokine receptor CCRL2 is the lack of cytokine
scavenging. We incubated CRAM-A CCRL2-V180M and CCRL2-WT expressing cells with
chemerin and measured the levels of chemerin in the supernatant over 24 hours. We failed to
detect any scavenging activity of chemerin by CCRL2-V180M compared to CCRL2-WT and
negative controls (Figure 5).

4.4.8 CCRL2-V180M interacting with chemerin does not increase CCL4 secretion from
leukocytes
Cells transfected with CRAM-A and CRAM-B WT and V180M interacting with
chemerin did not significantly enhance CCL4 secretion from leukocytes at the 12 and 24 hour
measurements (supplemental figure 3).

4.4.9 CCRL2-V180M (CRAM-A) variant interacting with CCL19 increases leukocyte CCL4
secretion
Transfected cells carrying the V180M variant that interacted with chemokine ligand
CCL19 showed a significant increase in CCL4 secretion from leukocytes. Interaction of CRAMA-V180M cells with CCL19 significantly enhanced CCL4 secretion from leukocytes at 24 hours
(Figure 6A; two tailed T test, p-value 0.0025, µ=709 pg/mL) than CRAM-A-WT (µ=212.4
pg/mL).
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4.4.10 CCRL2-V180M (CRAM-B) variant interacting with CCL19 decreases leukocyte CCL4
secretion
In contrast, cells expressing CRAM-B-V180M that interacted with CCL19 significantly
reduced the secretion of CCL4 from lymphocytes and monocytes at 24 hours (Figure 6B; two
tailed T test, p-value 0.0103, µ=119.3 pg/mL) compared to CRAM-B-WT (µ=364.7 pg/mL).

4.5 Discussion
We have identified a unique biological effect of the CCRL2-V180M allele and a possible
mechanism for altering the levels of CCL4 in CSF as identified in the original GWAS analysis
20

. Decreased CSF levels of CCL4 may be due to an increased binding affinity of CCRL2-

V180M for CCL19. We found that the CRAM-A and CRAM-B CCRL2-V180M variants both
have higher binding affinity to chemerin. In addition, we found that CRAM-A CCRL2-V180M
has a higher binding affinity for CCL19 compared to wild type, but CRAM-B CCRL2-V180M
has a similar binding affinity to the wild type. Additionally, the CRAM-A V180M variant and
the CRAM A-WT do not scavenge chemerin, supporting results from other studies 46,51. We
confirmed that the atypical chemokine receptor CCRL2 does not directly interact with CCL4;
however, we found differences in CCL4 secretion levels from leukocytes when incubated with
CRAM-A and CRAM-B cells and CCL19.
Chimera protein predictor software and Regulomedb annotation tool predicted that the
V180M variant might cause biological functional changes. Amino acid position 180 is located at
the binding site at the second extracellular loop. Annotation of the variant predicted that the
amino acid change from the hydrophobic valine to a slightly less hydrophobic methionine is
sufficient to change biological functions. We determined that cells expressing both isoforms of
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CCRL2-V180M bind at a higher affinity with chemerin. The increased binding affinity for
chemerin by the CCRL2-V180M variant might induce a higher inflammatory response due to the
increased concentration of the chemoattractant chemerin on the surface of cells 41. CCL19
binding is unique between CCRL2-V180M isoforms. The CRAM-A V180M variant has a higher
binding affinity to CCL19 than cells expressing CRAM-A-WT, whereas the CRAM-B variant
binds with similar affinity to the wild type. A deviation from normal levels of the
proinflammatory properties of CCL19 has been associated with establishing neurogenic
hypertension 52, increasing risk of developing prostate and cervical cancer 53,54, and inhibiting
dendritic cell migration and T cell activation 55, and developing AD 56. CRAM-A-V180M might
play a critical role in the development of these associated diseases as it concentrates and
enhances the proinflammatory signals from CCL19 ligand.
This altered ability of CRAM-A CCRL2-V180M to bind with chemerin and CCL19 did
not change its measurable ability to scavenge chemerin, we were unable to detect a scavenging
signal in both CRAM-A-WT and V180M. There is literature suggesting that CRAM-B is capable
of scavenging CCL19 43. While we did not determine if CRAM-B-V180M alters scavenging
efficiency of CCL19, we did find that both CRAM-A and CRAM-B interacting with CCL19
initiate divergent levels of CCL4 secretion from leukocytes. CRAM-B-V180M stimulated a 3fold lower level of CCL4 at the 24-hour point compared to 12-hour point. This could be due to
CCL19 being scavenged at a higher efficiency when interacting with CRAM-B-V180M than
with WT. We suspect that lower levels of CCL19 in the system will initiate lower secretion of
CCL4 from neighboring cells. Considering CRAM-B isoform is more common than CRAM-A 43
, this could explain the association between CCRL2-V180M and lower levels of CCL4 seen in
the original GWAS analysis 20. CRAM-A-V180M interacting with CCL19 yielded a 21-fold
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increase in CCL4 secretion from leukocytes. This may be due to CCRL2 increasing the
concentration and signaling of CCL19 interacting with CCRL2 41. We showed CRAM-AV180M has a higher binding affinity for CCL19 and concentrating this proinflammatory ligand
might enhance the inflammatory response and elevate CCL4 secretion from leukocytes. These
results demonstrate that the CCRL2-V180M phenotype depends on the isoforms, CRAM-A or B, expressed and the type of ligand, chemerin or CCL19. Thus, CCRL2-V180M has the potential
to alter the homeostasis not only of its known ligands, CCL19 and chemerin, but many other
proinflammatory chemokines indirectly interacting with it, such as CCL4. Hence, we can infer
that the CCRL2-V180M variant might have a much broader impact than simply decreasing
levels of CCL4 and decreasing the risk to develop AD, as reported in the GWAS analysis. A
greater effort is required to fully characterize this functional variant and determine its effect on
other chemokines and association with other immune related diseases.
GWAS analyses have associated thousands of genetic variants that alter the rate of
development of complex human diseases; providing understanding at the DNA level of how a
single nucleotide polymorphism (SNP) might affect biological and molecular properties at the
protein level. The characterization of the biological mechanism of these associated SNPs with
different phenotypes has been difficult. SNP characterization requires a deeper understanding of
how DNA changes might affect gene expression through transcription, RNA splicing, ligandreceptor binding, protein function, etc. 57. In this study, we determined the biological
characterization of CCRL2-V180M. We provided insights into the mechanism by which
CCRL2-V180M, specifically CRAM-B-V180M, lowers CCL4 secretion. Alterations of CCL4
chemokine gradient homeostasis in blood and CSF are associated with increased risk to develop
AD and others diseases. We demonstrate CCRL2-V180M alters the binding affinity of the two
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ligands known for this receptor. Alterations of concentrations of chemoattractant chemerin and
proinflammatory chemokine CCL19 in the immune response might develop a series of
irregularities increasing the risk to develop a disease. Further efforts should focus understanding
the effects of CCRL2-V180M and its impact on other chemokines in microglia, monocytes and
neurons.

4.6 Methods
4.6.1 Chimera
CCRL2-WT and CCRL2-V180M chemokine receptor amino acids sequences were sent
in FASTA format to the University of Michigan’s Zhang Lab LOMETS server. 3D models were
generated by collecting high-scoring structural templates from 11 locally-installed threading
programs (CEthreader, FFAS3D, HHpred, HHsearch, MUSTER, Neff-MUSTER, PPAS, PRC,
PROSPECT2, SP3, and SparksX) 58,59. These 11 models were compared to similar chemokine
receptors for accuracy. Using UCSF Chimera Software, the 3D models were oriented in space 60.
We superimposed CCRL2-WT and CCRL2-V180M to check for differences in folding and
hydrophilicity. 3D images were produced using UCSF Chimera Software to highlight the
predicted chemokine receptor structure and hydrophobic interactions at amino acid position 41
60

.

4.6.2 Annotation
Annotation and prediction of the biological function of CCRL2-V180M variant was determined
using RegulomeDB and Polymorphims Phennotyping v2 (PolyPhen-2). RegulomeDB is a
database that annotates variants with known and predicted regulatory elements in human genome
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such as eQTL, transcription factor binding, and transcription factor motif 61. This predicter
algorithm scores between 1 and 6 and any variant categorized between 1 and 5 is predicted to
have damaging biological function in the human genome. PolyPhen-2 is an algorithm that
predicts possible biological impact of an amino acid substitution in the human genome 62. This
algorithm classifies the biological impact of a variant from a damaging to a tolerable variant.

4.6.3 Transformation and Transfection
Plasmid constructs were ordered at Genscript, where DNA sequences for CCRL2-WT
and CCRL2-V180M were inserted into vector pCMV6-AN-myc-DDK (ORIGENE, Cat
#PS100016). Transformation protocols were followed as recommended by the manufacturer.
Briefly, plasmids were transformed into DH5a cells, amplified, and purified using the
ZymoPURE II Plasmid Maxiprep kit (Cat #D4203). Plasmids were transfected into Chinese
Hamster Ovary (CHO-k1 ATCC® CCL-61) cells using lipofectamine (ThermoFisher, Cat
#15338100) and manufacture recommendations were followed. Properly transfected cells were
selected using the antibiotic G418 sulfate (ThermoFisher, Cat #10131035). Transfected cells
were grown in F12 media (10 µg/ml penicillin, 10 µg/ml streptomycin; Gibco Cat #21127-022)
with 10% FBS (HYCLone Cat #SH30071.01). Cell media was changed every 48 to 72 hours
depending on cell confluency levels.

4.6.4 Cell isolation
We tested the atypical chemokine receptor CCRL2-V180M function using CHO-k1
cells because they lack expression of the wild type CCRL2 receptor as well as other
competing human chemokine receptors. It is important to note that this cell type is absent in
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the human brain and therefore our results should not be overinterpreted. After transfecting
CHO-k1 cells with plasmids carrying CCRL2-WT or CCRL2-V180M, cells were incubated until
they reached 80% confluency and prepared for cell sorting. Cells were stained for 30 minutes on
ice with conjugated anti-human PE labeled CCRL2 antibody (BioLegend; Cat #358303). Cells
were then washed and isolated using anti-PE MicroBeads from MACS Miltenyi Biotech (Cat
#130-048-801) following manufacture recommendations. After isolation, cells were incubated in
F12 media until 80% confluency was reached.

4.6.5 Receptor expression
CHO-k1 cells transfected with CCRL2-WT or CCRL2-V180M were harvested when a 75
cm2 flask reached 80% cell confluency. 250,000 cells were resuspended in 300 µL of PBS-1%
BSA and placed in FACs tubes. To evaluate expression of the CCRL2 receptor, cells were
stained with anti-CD16/32 (Fc block) on ice for 20 minutes (eBioscience, Cat #14-0161-85).
After two washes, cells were stained for 30 minutes on ice with anti-human CCRL2 antibody.
After two washes receptor expression was analyzed on a BD Accuri.

4.6.6 Receptor binding
To determine CCL19 binding levels for CCRL2-WT and CCRL2-V180M, cells were
incubated with conjugated CCL19-AF647 (ALMAC, Cat# CAF-6) at 37°C for 45 minutes at
different concentrations ranging between 100 to 1000 nM. After two washes, receptor expression
was analyzed on a BD Accuri. To determine the levels of CCRL2-WT and CCRL2-V180M
receptor expression, cells were stained with anti-CD16/32 (Fc block) on ice for 20 minutes. After
two washes, cells were stained for 30 minutes on ice with anti-human CCRL2 antibody. In the
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CCL4 competitive binding assay levels for CCRL2-WT and CCRL2-V180M, cells were
incubated with unconjugated CCL4 (PEPROTECH, Cat #300-09100UG) at 37°C for 45 minutes.
After two washes and an Fc block as described above, cells were stained for 30 minutes at 37°C
with unconjugated chemerin. After two washes, cells were stained with conjugated Ab-CCRL2
for 25 minutes at 4°C and washed twice. The levels of binding of the CCRL2 antibody were
analyzed in BD Accuri. The percentage of CCRL2 blocked by chemerin and CCL4 was obtained
subtracting 100 minus the percentage of conjugated Ab-CCRL2 bound to receptor. This group of
cells were compared with cells incubated with chemerin only and later stained with conjugated
Ab-CCRL2.
The percentage of chemerin biding to the receptor was determined by using a human-FC
chain in chemerin 41 with a secondary anti-human IgG (Biolegend Cat #405307). Another set of
cells were prepared to using Ab-CCRL2 to identify the percentage of receptor level. Binding
affinity of chemerin to receptor was determined by dividing the percentage of Ab-human IgG
bound to chemerin was divided over the percentage of Ab-CCRL2 bound to CCRL2.

4.6.7 Chemerin scavenging
CRAM-A-WT and CRAM-A-V180M cells were seeded in a 6 well cell culture plate with
fresh F12 media with 10% FBS and 1000 pg/mL of chemerin added to each well. At varying
time points, 150 µL of media supernatant was extracted from each well to measure the remaining
concentration of chemerin using a chemerin TMP sandwich ELISA kit (R&D Systems, Cat
#DCHM00). 96 well ELISA microplates were coated overnight at room temperature with a
monoclonal antibody specific for human chemerin (0.25 µg/mL in PBS). Plates were washed
three times with 0.05% tween diluted in PBS and then wells were incubated with blocking buffer
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(PBS/1% BSA) for 2 hours at room temperature. After three washes, samples and controls were
added to the wells and incubated for 2 hours at room temperature. After three washes plates were
incubated for 1 hour at room temperature with biotinylated anti-human chemerin antibody (0.25
µg/mL) diluted in blocking buffer. After three washes, plates were incubated with 100 µL of
Streptavidin-HRP conjugate (0.05 µg/mL) for 30 minutes at room temperature. Plates were
washed three times and 100 µL of TMB substrate solution (hydroperoxide and chromogen
tetramethylbenzidine) was added for 20 minutes at room temperature in the dark. The reaction
was stopped with 100 µL of 1M of hydrochloric acid. Optical density was determined using a
microplate reader set at 450 nm with a wavelength correction of 620 nm.

4.6.8 CCL4 secretion
CRAM-A-WT, CRAM-A-V180M, CRAM-B-WT and CRAM-B-V180M cells were
seeded in a 6 well cell culture plate with fresh F12 media with 10% FBS. 750 nM/mL of
chemerin was added to each well. Cells interacting with chemerin were incubated for 1 hour.
After a single wash, fresh media was added containing a mix of lymphocytes and monocytes
(~50,000 cells/mL). A second set of cells were incubated with 1000 pM/mL of CCL19 for 1
hour. After a wash, ~50,000 cells/mL of lymphocytes and monocytes were added. At varying
time points, 150 µL of media supernatant was extracted from each well to measure concentration
of CCL4 secreted by lymphocytes and monocytes using a CCL4 TMP sandwich ELISA kit
(R&D Systems, Cat #900-T36). The ELISA protocol was followed as recommended by the
supplier. Samples were subtracted by the amount of CCL4 secreted from controls (transfected
cells incubated with lymphocytes and monocytes only–no chemerin or CCL19 added). Peripheral
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blood mononuclear (PBMC) lymphocytes and monocytes were collected from a single donor
individual and the assay was done with six technical and two biological replications.

4.6.9 Statistical Analysis
Statistical analyses were performed using the Prism 8 software (GraphPad Software, La
Jolla, CA, USA). Differences in binding affinity and scavenging efficiency between CCRL2V180M and CCRL2-WT were analyzed using an unpaired T-test. Kd, EC50, and IC50 were
calculated using non-linear analysis best fit test. Each independent run contained a minimum of
three replicates per sample and the mean of those replicates were considered a single point of
analysis. In this study, each experiment was performed with three to five independent runs (nine
to fifteen replicates per sample). Results presented are representative of observed phenotypes and
analysis with P-values less than 0.05 were considered significant.
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Figure 4.1 Model of CCRL2-V180M does not predict a change in protein folding and predicts
decrease in hydrophilicity.
CRAM-A isoform (A, B, E) CRAM-B (C, D, F). There is no dramatic difference in predicted
protein folding and a minor decrease in hydrophilicity between CCRL2-WT and CCRL2V180M. A & C) Side by side ribbon view of CCRL2-WT (blue and green) and CCRL2-V180M
(gold and red) protein model for CRAM-A and CRAM-B. B & D) Overlay of CCRL2-WT and
CCRL2-V180M ribbon models highlighting the folding at amino acid position 180 (WT is green
and V180M is red). E & F) View of hydrophobic (red) and hydrophilic (blue) amino acids at
amino acid positions 178-182 for the CCRL2-WT (top) and CCRL2-V180M (bottom)
chemokine binding site. There is a hydrophilicity change from hydrophobic (WT) to hydrophilic
(V180M) in both CRAM-A and CRAM-B.
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Figure 4.2 Chemerin binds with higher affinity to CCRL2-V180M compared to CCRL2-WT in
ligand binding assay.
CCRL2-WT and CCRL2-V180M transfected cells were incubated with a human-FC chain in
chemerin and then stained with a conjugated secondary anti-human IgG. A second batch of cells
were prepared to obtain the percentage of receptor CCRL2 at the cell surface. The percentage of
chemerin+ cells over CCRL2+ cells was used to obtain ratios of binding. A & B) There is a
significantly higher binding affinity between CCRL2-V180M than CCRL2-WT for chemerin in
both CRAM-A (two tailed T test; p-value 0.0376) and CRAM-B (two tailed T test; p-value =
0.0491). C & D) The same experiment was repeated using different concentrations of chemerin
ligand (ranging from 50 nM to 1500 nM). C) CRAM-A-V180M has a 4.6-fold lower equilibrium
dissociation constant (Kd = 96.6 nM) the CRAM-A-WT (Kd= 444.3 nM). D) CRAM-B-V180M
has a 2.7-fold lower Kd value (220.8 nM) compared with CRAM-B-WT (Kd = 598.3 nM).
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Figure 4.3 CCL19 binds with higher affinity to CRAM-A-V180M compared to CRAM-A-WT in
ligand binding assay.
CCRL2-WT and CCRL2-V180M transfected cells were incubated with conjugated CCL19. A
second batch of cells were prepared to obtain the percentage of receptor CCRL2 at the cell
surface. The percentage of CCL19+ cells over CCRL2+ cells was used to obtain ratios of
binding. A) There is a significantly higher binding affinity between CRAM-A-V180M than
CRAM-A-WT for CCL19 (two tailed T test; p-value 0.0162). B) We failed to detect a significant
difference between CRAM-B-V180M and CRAM-B-WT (two tailed T test; p-value = 0.4446).
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Figure 4.4 CCL4 does not directly interact with CCRL2.
We failed to detect a direct interaction of CCL4 with CCRL2 in a competition biding analysis in
both CRAM-A and CRAM-B cells. A) The percentage of CCRL2 in CRAM-A-WT incubated
with chemerin is similar to cells incubated with chemerin and CCL4. Similar results were
observed in CRAM-A-V180M cells. B) The percentage of CCRL2 in CRAM-B-WT incubated
with chemerin is similar to cells incubated with chemerin and CCL4. Similar results were
observed in CRAM-B-V180M cells.
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Figure 4.5 CRAM-A-WT and CRAM-A V180M do not scavenge chemerin ligand.
We failed to detect scavenging of chemerin in both CRAM-A-WT and CRAM-A-V180M.
chemerin levels were monitored for 24 hours.
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Figure 4.6 CCRL2 interacting with CCL19 alters leukocytes CCL4 secretion.
A) CRAM-A-V180M interacting with CCL19 significantly increases leukocytes CCL4 secretion
than CRAM-A-WT (two tailed T test, p-value = 0.0025). B) CRAM-B-V180M interacting with
CCL19 significantly decreases leukocytes CCL4 secretion than CRAM-B-WT (two tailed T test,
p-value = 0.0103.

107

Supplemental Figure 4.1 Atypical chemokine receptor CCRL2-V180M and CCRL2-WT have
similar levels of receptor expression on the cell surface.
A) There is no significant difference in the percent of positive cell for the atypical chemokine
receptors CCRL2-V180M and CCRL2-WT (n=3; ns = not significant) at the cell surface for
CRAM-A cells. B) CCRL2-V180M and CCRL2-WT have percentage of receptor expression at
the cell surface in CRAM-B cells (n=3; ns = not significant).
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Supplemental Figure 4.2 Chemerin binds with higher affinity to CRAM-A-V180M in a
competition binding assay.
Atypical chemokine receptors CRAM-A-WT and CRAM-A-V180M were compared in a
competition binding assay. Cells were incubated with unconjugated chemerin for 45 minutes at
37°C; then, conjugated anti-CCRL2 was added to determine levels of receptor binding inhibition
by chemerin. 100 minus the CCRL2 percentage expression was used to determine chemerin
binding. CRAM-A-V180M bound to chemerin with higher affinity than CRAM-A-WT (two
tailed T test; p-value = 0.0062).
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Supplemental Figure 4.3 CCRL2 interacting with chemerin does not alters leukocytes CCL4
secretion.
A) CRAM-A-V180M and CRAM-A-WT interacting with chemerin do not alter leukocytes
CCL4 secretion. B) CRAM-B-V180M and CRAM-B-WT interacting with chemerin do not alter
leukocytes CCL4 secretion.
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CHAPTER 5: Conclusions
As has been presented in this dissertation, the diagnosis of AD and characterization of
biological mechanisms that lead to pathology and modulate risk for disease are vital to the
development of a cure and have proven to be extremely difficult. In the preceding chapters we
outlined our data suggesting cell free single stranded DNA (cfssDNA) as a potential biomarker
for AD as well as important information about the molecular mechanisms by which common
variants in the human genome influence the inflammatory response in the brain.
In Chapter 2 we presented our investigation of cfssDNA as a biomarker for AD status in
three independent cohorts. We observed significantly lower concentration of cfssDNA isolated
from CSF in AD cases than we found in controls. These data suggest cfssDNA as a potential
biomarker for diagnosis of AD. The identification of cfssDNA as potential biomarker for AD
diagnosis is novel. Further experiments are required to fully determine cfssDNA as a true
biomarker for AD diagnosis. First, we propose the replication of this study in a much larger CSF
cohort. The measurement of isolated cfssDNA from CSF in a much larger sample size may help
us determine a threshold level for AD vs. control status. This experiment should also include
subjects with other types of dementia for direct evaluation of whether this biomarker is specific
to AD or present in all types of neurodegeneration. In addition, we propose the sequencing of the
isolated cfssDNA genetic material in all subjects. This sequence data can be used to determine
the cell type from which the DNA is originating and may provide important insights into disease
specific patterns, shedding light both on the specificity of this biomarker and etiology of disease.
While a complete answer to our observation of lower concentration of cfssDNA in AD
cases is beyond the scope of this work, we speculate that increased microglia activity may
degrade cell-free DNA (cfDNA) more completely in AD subjects, or that decreased brain
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volume is resulting in higher CSF volume and therefore lower concentrations of cfDNA. These
questions could be addressed in a mouse model of AD. A time course of cfssDNA levels in AD
and healthy patients would be also be useful for understanding this unanticipated association.
The APP23 AD mouse model allows the monitoring of plaques formation, neuronal loss, gliosis,
and cognitive impairment as early as three months of age. We propose to monitor a cfssDNA
levels isolated from the APP23 AD mouse CSF. This experiment will require CSF extraction at
multiple time points prior and posterior to three months of age. It will also require a different set
of normal mice to serve as control group. We would expect cfssDNA measurements from APP23
AD mice to increase prior to the three-month time mark and rapidly decrease passing this time
threshold. In a separate experiment using the APP23AD mouse model, different doses of
lipopolysaccharide can be administrated to enhance microglia activation in the brain. We would
expect that mice with enhanced microglia activation would contain less cfDNA material than
those with normal microglia activation. These proposed experiments can elucidate the potential
mechanisms by which cfssDNA is acting as a biomarker for AD.
In Chapters 3 and 4 we characterized the biological mechanisms that underlie the
reported associations between the ACKR2-V41A variant and CCL2 levels and the CCRL2V180M variant and CCL4 levels. Our data demonstrate that the ACKR2-V41A receptor has a
lower CCL2 binding affinity, scavenging efficiency, and receptor upregulation compared to
ACKR2-WT. For CCRL2-V180M our data demonstrate higher binding affinity with chemerin
and CCL19 than CCRL2-WT. Our data also show that while CCRL2-V180M and CCRL2-WT
do not directly bind with CCL4, interactions between CCRL2-V180M and CCL19 alter the
secretion of CCL4 from leukocytes.

112

Our work in the biological characterization of the atypical chemokines receptors ACKR2
wild type (WT) and CCRL2-WT answers a few key issues in the field. ACKR2 is an atypical
chemokine receptor which lacks of chemokine attractant signaling motif. ACKR2 production and
gene expression follows the β-Arrestin-dependent signaling pathway cofilin pathway [Rac1p21-activated kinase 1 (PACK1)-LIM kinase 1 (LIMK1) cascade]. There is a dispute in the
field concerning whether or not ACKR2 contains a calcium influx signaling1-6. We detected a
calcium influx signal in both ACKR2-WT and ACKR2-V41A. This observation suggests that
upon activation of ACKR2 receptor there are a series of cells activation pathways involving
calcium influx. These pathways are yet be identified or characterized.
These data have also clarified concepts related to the biological functions of the atypical
chemokine receptor CCRL2-WT. CCRL2 has two main isoforms known as CRAM-A and
CRAM-B. Literature suggested that there are biological differences in terms of binding and
scavenging between CRAM-A and CRAM-B. According to literature, CRAM-A only binds to
chemoattractant chemerin; whereas, CRAM-B bind to chemerin and chemokine ligand CCL19 79

. We observed binding of chemerin and CCL19 in both CRAM-A and CRAM-B isoforms. In

addition, regardless of the well established atypical characteristics of this receptor, literature
suggested that CRAM-B is capable of scavenging CCL19 9. We failed to detect a scavenging
signal in both CRAM-A and CRAM-B when tested with CCL19 and chemerin. Our data support
the notion that CCRL2 serves as an anchor where chemerin or CCL19 can concentrate to amplify
their chemoattractant or proinflammatory signals.
We identified that ACKR2-V41A and CCRL2-V180M behaves differently than its WT
version. We observed that ACKR2-V41A and CCRL2-V180M have the potential to deviate
normal expression of the AD-related chemokine ligand CCL2 and CCL4. We characterized the
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associated ACKR2-V41A increased levels of CCL2 in CSF and plasma. Increased levels of
CCL2 in the CSF and plasma correlate with increased risk for AD. In addition, the associated
CCRL2-V180M variant correlates with low levels of CCL4. We believe this variant might serve
as a protective variant against AD development. High levels of CCL4 in CSF and plasma
correlated with increased risk for AD. The biological characterization of these variants was
limited in terms of cell line (cell hamster ovary cells line – CHOK1), and further analyzes are
required.
Future efforts should begin by replicating these experiments in a cell line more relevant to
brain function, such as neuroblastoma N2. In addition, the biological effects of the atypical
chemokine receptors ACKR2-V41A interacting with CCL2 and CCRL2-V180M interacting with
CCL19 to regulate CCL4 should be evaluated in an AD simulated environment. The N2a cell
line in combination with a vector for high expression of APP and another vector with high tau
expression (3RN2N) can provide the simulated AD environment. Cell line transfection with
vectors carrying the WT or variant version of the atypical chemokine will be required to
complete the desired cell linage. On the other hand, an AD mouse model could answer if
regulation of chemokine ligands CCL2 and CCL4 modulate AD pathology. We speculate if
atypical chemokine receptor ACKR2 and CCRL2 are blocked the inflammatory response, Ab,
and tau expression would decrease, producing a broader impact in the development of
inflammatory related diseases. If proinflammatory properties of CCL4 and CCL2 are regulated,
AD development could be targeted more specifically.
This work provides meaningful contribution to the better understanding of AD diagnosis and
the role of atypical chemokine receptors associated with AD-related chemokines ligand. The data
presented in this dissertation answer to key questions and identify important avenues for future
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research and translational efforts. These findings provide evidence for a novel biomarker for AD
diagnosis, mechanistic insights into the functional impact of common genetic variants on
chemokine levels, and highlight a potential role of atypical chemokines in altering the risk for
AD.
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